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CHAPTER 1. INTRODUCTION
Nature has placed mankind under the governance of two sovereign
masters, pain and pleasure. It is for them alone to point out what we
ought to do, as well as to determine what we shall do. […]. They govern
us in all we do, in all we say, in all we think: every effort we can make to
throw off our subjection, will serve but to demonstrate and confirm it. In
words a man may pretend to abjure their empire: but in reality he will
remain subject to it all the while.
Jeremy Bentham, 1789 1
Pain is a conscious, subjective, and unpleasant experience that consists of sensorydiscriminative, affective-motivational and cognitive-evaluative components (Melzack & Casey,
1967). The sensory-discriminative component of pain provides information about the temporal
occurrence, the spatial localization, the physical qualification, and the intensity quantification of
the noxious stimulus and elicits rapid responses (i.e., withdrawal reflexes) designed to prevent
further or potential injury. The affective-motivational dimension can be distinguished from its
discriminative sensory aspects (Craig & Sorkin, 2001) and renders the noxious stimulus with a
distinctly unpleasant character that ultimately motivates behaviors such as avoidance and
recuperation (Borszcz, Johnson, & Fahey, 1994).

The cognitive-evaluative component is

responsible for the appraisal of the meanings, consequences, and predictability of the painful
sensations and injury. Each of these components is mediated and modulated through different
forebrain mechanisms (Casey, 1999).
The affective and cognitive components of pain interact and attribute the negative
emotional coloring to the pain experience (Almeida, Roizenblatt, & Tufik, 2004), thus generating
1

The first sentence of this paragraph has been used as a motto also by Leknes & Tracey (2008).
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emotional disturbances such as fear, anger, frustration, stress, anxiety, and depression (Price,
2000, 2002). Affective reactions to pain can generate “fear-avoidance” beliefs (Asmundson,
Norton, & Allerdings, 1997; Waddell, Newton, Henderson, Somerville, & Main, 1993) and
“catastrophizing” thoughts (Carleton, Abrams, Asmundson, Antony, & McCabe, 2009; Sullivan,
Stanish, Waite, Sullivan, & Tripp, 1998) that further increase the distress of the patient in pain,
and thus leading to a vicious circle characterized by development and maintenance of pain
behaviors (McCracken, Zayfert, & Gross, 1992) such as decreased self-efficacy (Arnstein,
Caudill, Mandle, Norris, & Beasley, 1999), avoidance behavior (Asmundson, Norton, & Norton,
1999; Vlaeyen & Linton, 2000), work loss, and general disability in activities of daily living
(Fordyce, Shelton, & Dundore, 1982; Philips, 1987; Waddell et al., 1993). Furthermore, the
development and maintenance of these secondary emotional disturbances exacerbate the
suffering of patients in pain, and thereby motivate individuals to seek medical attention. Indeed,
“it is suffering, not pain, that brings patients into doctor's offices in hopes of finding relief”
(Loeser, 2000). Supporting this observation, many researchers found that fear of pain may be
more disabling than pain itself (Crombez, Vlaeyen, Heuts, & Lysens, 1999; Fordyce et al., 1982;
McCracken et al., 1992; Philips, 1987; Waddell et al., 1993; Wade, Dougherty, Hart, Rafii, &
Price, 1992) and that fear of pain can be used as a reliable predictor for the perceived intensity of
acute pain (George, Dannecker, & Robinson, 2006; Hirsh, George, Bialosky, & Robinson, 2008).
As a consequence, the need for better medical treatment of pain and better pain
management therapies makes understanding the mechanisms through which the emotional aspect
of pain is generated, maintained and finally suppressed of paramount importance. Whereas
considerable progress has been made in understanding the neural mechanisms that subserve the
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sensory-discriminative component of the pain, comparatively little is known about the neural
circuits underlying the generation and suppression of the affective aspect of the pain experience.
More than a century ago, it was observed that strong analgesics, like morphine, heroin,
amphetamine, and cocaine, have a high abuse potential and are self-administered by both
humans and animals (Himmelsbach, 1943; May, 1953; Morphine and Heroin Addiction:
Departmental Committee's Report, 1926; Spender, 1887), suggesting that the neural substrates of
reward and antinociception overlap (Oberst, 1943). Franklin (1989, 1998) proposed that the
ability of these drugs (i.e. opioids and psychostimulants) to induce a positive affect underlies
both their addictive liability and their analgesic action. The positive affective state generated by
these drugs should reduce the level of distress that normally accompanies noxious stimulation.
This phenomenon is referred to as “affective analgesia” and reflects preferential suppression of
the emotional reaction to pain. The affective analgesia hypothesis proposes that neural substrates
underlying reward contribute to suppression of the affective response to pain. The proposed
research provides the first systematic investigation into the capacity of brain reward circuit
activation to suppress the affective response of rats to noxious stimulation.
1.1. Ventral Tegmental Area (VTA) in Reward and Reinforcement
Although the terms reward and reinforcement are more often than not used
interchangeably, there is a clear distinction between an internal positive subjective state (reward)
and the capacity of that state to support appetitive conditioning (reinforcement) (Wise, 1996).
The ability of natural (i.e., food, water, sex) or artificial (i.e., drugs of abuse, intracranial selfstimulation - ICSS) rewards to induce a positive affective state relies, at least partially, on the
integrity of dopaminergic projections from the VTA to nucleus accumbens (NAc) of the striatum
(for reviews, see Bardo, 1998; Di Chiara et al., 1999; Di Chiara, 2002; Ikemoto, 2007; Kiyatkin,
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2002; Koob & Volkow, 2010; Schultz, 2000; Wise, 2004). This idea is supported by a plethora
of data derived from microinjection, microdialysis, electrophysiological, and neuroimaging
studies (Table 1). For example, in vivo microdialysis experiments in rats revealed that chemical
(Westerink, Kwint, & deVries, 1996) or electrical (Fiorino et al., 1993) activation of the VTA
results in an increase of dopamine (DA) release in NAc. This release is associated with reward,
as rats that electrically self-stimulate the VTA display an increase in accumbal DA up to almost
200% (Fiorino et al., 1993). Likewise, drugs that are abused in humans (e.g. amphetamine,
cocaine, opiates, nicotine, ethanol 2 ) increase DA availability in the rat NAc, drugs that induce a
negative affective state in humans (e.g. κ-opioid agonists, tifluadom, bremazocine) decrease DA
availability in the rat NAc, and drugs that do not induce any affective state in humans (e.g.
imipramine, atropine, antihistamines) do not change the DA levels in the rat NAc (Di Chiara &
Imperato, 1988). These findings are in agreement with the data provided by imaging studies in
humans with DA tracers (e.g. raclopride isotopes), which showed that drugs of abuse like
amphetamine or cocaine increase DA availability in the striatum and this increase is associated
with self-reports of “high” and “euphoria”, in a directly proportional fashion (for a review of
these studies, see Volkow, Fowler, Wang, Baler, & Telang, 2009). Conversely, the levels of
striatal DA release were unchanged in the subjects in which the psychostimulants did not induce
euphoric effects. Not only have directly rewarding stimuli elicited mesolimbic DA release, but
also the stimuli that were previously associated with a reward (Schultz, Dayan, & Montague,
1997).

2

These drugs of abuse act as DA agonists as they increase the DA availability in the brain either by acting directly
on the VTA neurons (e.g. opioids disinhibit the DA cells, Johnson & North, 1992; nicotine activates the DA
neurons, Mereu et al, 1987; ethanol lifts the GABA inhibition from the DA neurons, Xiao & Ye, 2008) or by
blocking the DA transporter or the DA D2 autoreceptor (e.g. for amphetamine, see Jones, Gainetdinov, Wightman,
& Caron, 1998; for cocaine, see Beuming et al., 2008).
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Besides mediating the positive affective state that characterizes a reward, the role of DA,
especially accumbal DA, in reinforcement is also well-substantiated by the literature.

For

instance, a rat will learn to press a lever in order to receive food, water, sexual contact, or drugs
of abuse and during learning of these appetitive instrumental tasks the DA release in NAc is
increased (Cheng & Feenstra, 2006; Hernandez & Hoebel, 1988), as well as during the
performance of the appetitive tasks (Phillips, Stuber, Heien, Wightman, & Carelli, 2003). Also,
rats readily self-administer DA agonists like heroin and cocaine if the DA system is intact, but
they cease to do so if the mesoaccumbal DA system is depleted (Wise & Rompre, 1989). The
involvement of the DA system in reinforcement is further supported by the finding that
disruption of DAergic transmission either by systemically blocking the DA receptors or by
activating the DA autoreceptors results in impairments in appetitive conditioning in both rodents
(Gerber, Sing, & Wise, 1981; Ikemoto & Wise, 2004; Wise & Schwartz, 1981) and humans
(Pizzagalli et al., 2008; Santesso et al., 2009). Likewise, even if animals successfully learned an
appetitive conditioning task, they do not perform normally if the mesoaccumbal DAergic system
is impaired (Parkinson et al., 2002). Furthermore, extinguished lever pressing for cocaine is
reinstated by microinjections of cocaine or other DA agonists into NAc (Schmidt, Anderson, &
Pierce, 2006), behavior that is blocked by pretreatment with DA antagonists into the same region
(Anderson, Schmidt, & Pierce, 2006). Taken together, these findings point to the paramount role
of DA release in NAc for both reward and reinforcement processes.
1.2. VTA in Pain and Analgesia
Involvement of the VTA in antinociception is supported by the finding that electrical
stimulation of the VTA abolishes escape responding produced by stimulation of the nucleus
reticularis gigantocellularis (Anderson, Diotte, & Miliaressis, 1995).

Nucleus reticularis
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gigantocelluaris (nRGC) is a medullary link of the spinoreticulothalamic pathway that transmits
noxious information from the spinal cord to the medial thalamus and related forebrain structures
(Almeida et al., 2004). Similarly, electrical stimulation of lateral hypothalamic sites that support
self-stimulation, an effect dependent on VTA activation (Wise, 1996), also attenuates escape
responding to nRGC stimulation (Simson & Coons, 1989).

Stimulation of the lateral

hypothalamus produces antinociception in the footshock test (Lopez & Cox, 1992), tail-flick test
(Aimone, Bauer, & Gebhart, 1988; Franco & Prado, 1996) and hot-plate test (Carstens,
Fraunhoffer, & Suberg, 1983).

Simulation of the lateral hypothalamus also reduced the

amplitude of evoked potentials to noxious peripheral stimulation in medial thalamic targets
(centromedian–parafascicular complex) of nRGC and suppressed escape responding to the same
noxious stimulus (Butkevich & Kassil, 1999). Nociceptive processing by these medial thalamic
sites contributes to production of affective responses to pain in both humans and animals
(Delacour, 1971; Harte, Kender & Borszcz, 2005; Harte, Lagman & Borszcz, 2000; Kaelber et
al., 1975; Mark, Ervin, & Yakovlev, 1962; Weigel & Krauss, 2004; Whittle & Jenkinson, 1995;
Young et al., 1995).
Release of DA into NAc from axon terminals of DAergic neurons in VTA contributes to
the antinociceptive action of VTA stimulation (see Table 3). Opioids administered systemically
or into the VTA increase DA metabolism (Kalivas & Richardson-Carlson, 1986; Latimer, Duffy
& Kalivas, 1987) and extracellular levels of DA (Pontieri, Tanda & Di Chiara, 1995) in the NAc.
Similarly, systemic administration of amphetamine or cocaine elevates extracellular levels of DA
in the NAc (Pontieri, Tanda, & Di Chiara, 1995). Microinfusions of morphine into the VTA or
amphetamine into NAc suppress paw-licking in the formalin test but do not alter withdrawal
latencies in the tail flick test (Altier & Stewart, 1996; Manning, Morgan, & Franklin, 1994).
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These antinociceptive effects in the formalin test were blocked by pretreatment of NAc with the
DA receptor antagonist raclopride (Altier & Stewart, 1998). Likewise, neurotoxic lesions of DA
neurons in VTA block the suppression of paw-licking in the formalin test produced by systemic
administration of morphine or amphetamine, but do not alter the increase in tail flick latencies
generated by these drug treatments (Clarke & Franklin, 1992; Morgan & Franklin, 1990).
Alternately, intra-NAc microinjections of the D2 agonist quinpirole reduced nociceptive
responding during the formalin test in a dose-dependant manner and this effect was blocked by
administration of the D2 antagonist raclopride into NAc (Taylor, Joshi, & Uppal, 2003). As tail
flicks and paw-licking are respectively organized at spinal and supraspinal levels of the neuraxis
(for a review, see Le Bars, Gozariu, & Cadden, 2001) these findings indicate that activation of
mesoaccumbal DA projections selectively suppresses or masks nociceptive processing at
supraspinal levels of the neuraxis.
1.3. Analgesia and Reward: Motivational Continuum Hypothesis
Opioids and psychostimulants elicit mesolimbic DA release and this activation induces a
positive affect (see Table 1) and, as stated above, Franklin’s affective analgesia hypothesis
(1989, 1998) postulates that this positive affect suppresses the emotional distress associated with
the pain experience without reducing the actual sensory experience. Altier and Stewart (1999a)
postulated that the relation between the rewarding and antinociceptive actions of analgesic drugs
such as opiates and psychostimulants can be understood from the perspective of a motivational
continuum. This motivational continuum has poles of extreme negative and positive affect with
normal affect located in the middle. When administered in the normal affective state, opiates
and psychostimulants shift the continuum from normal affect to positive affect through activation
of the brain reward circuitry. The shift to the positive pole of the continuum may underlie the
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addictive liability of opiates or psychostimulants.

In contrast, when noxious stimulation

generates a negative affective state, opioids and psychostimulants suppress pain affect through
their activation of brain reward circuitry. This activation shifts the negative affective state to the
middle of the motivational continuum producing affective analgesia. It is important to stress that
while the same circuitry is activated in both cases, the baseline is changed in the latter example;
these drugs administered in the negative state do not induce a positive state (Fig. 1).

Figure 1. The motivational continuum. If the organism is in a negative affective state (e.g.
such as that generated by noxious stimulation), the opiates and psychostimulants shift the
motivational continuum towards a neutral affective state, producing affective analgesia by
activating the brain reward circuitry. If the organism is in a neutral affective state, the opiates
and psychostimulants shift the motivational continuum towards a positive affective state that
underlies their addictive liability, by activating the brain reward circuitry.
The motivational continuum hypothesis is supported by the observation that patients who
are given morphine for pain relief, and hence in a strong negative affective state, rarely become
addicted or develop withdrawal symptoms (Melzack, 1990). Alternately, addiction, tolerance,
and withdrawal commonly follow morphine administration during neutral or positive affective
states. Thus, when opioids are used for pain management, they may help the patient to achieve
an affective state normally experienced when free of pain, but not the extreme positive affect that
might support addiction. Supporting this view are reports that the capacity of morphine to serve
as a reinforcer in a conditioned place-paradigm (CPP) is attenuated when given to rats that are in
a chronic/tonic pain state (Narita et al., 2005; Ozaki et al., 2002; Suzuki, Kishimoto, & Misawa,
1996; Suzuki, Kishimoto, Misawa, Nagase, & Takeda, 1999) and that morphine fails to induce
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dependence in rats when administered during a pain state (Abbott, Franklin, Ludwick, &
Melzack, 1981; Colpaert, 1996; Vaccarino & Couret, 1993; Vaccarino et al., 1993).
In summary, the DA release from the VTA into the NAc underlies both the analgesia and
the rewarding effects induced by drugs of abuse. Clearly, neural circuits that underlie affective
analgesia and reinforcement overlap, but the extent of the overlap is currently unknown. The
present study systematically investigates the extent of the overlap between affective analgesia
and reinforcement.
1.4. Acetylcholine in VTA: The Common Mediator
In addition to opioids and psychostimulants, the availability of mesoaccumbal DA can be
also increased by endogenous substances like acetylcholine. VTA neurons display a variety of
nicotinic receptors subtypes (Adell & Artigas, 2004; Azam, Winzer-Serhan, Chen, & Leslie,
2002; Klink, de Kerchove d'Exaerde, Zoli, & Changeux, 2001) and at least the muscarinic
receptor M5 (Vilaro, Palacios, & Mengod, 1990; Yeomans, Forster, & Blaha, 2001) and M2
subtypes (Garzon & Pickel, 2006). Microinjecting nicotinic and muscarinic receptor agonists
into the VTA excites DAergic neurons in the VTA via activation of local cholinergic receptors
(Calabresi, Lacey & North, 1989; Lacey, Calabresi, & North, 1990; Niijima & Yoshida, 1988),
and increases the release of DA in NAc (Gronier & Rasmussen, 1998; Nisell, Nomikos, &
Svensson, 1994). Continuous infusion of the non-specific cholinergic agonist carbachol 3 into the
VTA causes an up to 140% elevation in extracellular DA levels in the ipsilateral NAc (Westerink
et al., 1996), and DA efflux in the NAc is increased by intra-VTA injection of the prototypical
3

Carbachol induces excitation of the DA neurons within VTA by activating both muscarinic and nicotinic receptors

via a L-type Ca2+ channel facilitation mechanism (Zhang, Liu & Chen, 2005)
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muscarinic agonist muscarine. Alternately, baseline levels of accumbal DA are reduced by intraVTA administration of the muscarinic antagonist scopolamine (Miller & Blaha, 2005).
Cholinergic projections to the VTA arise bilaterally mostly from the laterodorsal
tegmental (LDTg) and less from the adjacently located caudal pedunculopontine (PPTg) nuclei
(Blaha et al., 1996; Oakman, Faris, Kerr, Cozzari, & Hartman, 1995; Omelchenko & Sesack,
2005). Approximately 50% of LDTg neurons make synaptic contact (presumably excitatory)
with DA neurons in VTA that project to NAc or prefrontal cortex (PFC), the strength of
excitatory input being greater for DA neurons providing mesoaccumbal versus mesoprefontal
projections.

These LDTg neurons also provide moderate excitatory inputs to GABAergic

neurons in VTA that project to NAc.

The remaining 50% of LTDg/PPTg neurons make

synapses (presumably inhibitory) more with the mesoprefrontal than mesoaccumbens neurons
(Omelchenko & Sesack, 2005, 2006; Fig. 2). Besides projecting to mesolimbic and mesocortical
structures, the GABA cells within VTA also send collaterals to the DA neurons, making mostly
inhibitory synaptic contacts (Bayer & Pickel, 1991; Johnson & North, 1992; Omelchenko &
Sesack, 2009; Sugita, Johnson, & North, 1992). Thus, acetylcholine is likely to depolarize the
DA neurons in VTA either directly or indirectly by inhibiting the GABA interneurons and thus
lifting the inhibition from the DAergic cells.

11

Figure 2. Schematic drawing of cholinergic synapses within the VTA. The drawing depicts
the excitatory (white) and inhibitory (black) synapses made by cholinergic cells with the VTA
DAergic (D) and GABAergic (G) neurons. The thickness of cholinergic axons depicts the
approximate number of the connections. From Omelchenko & Sesack (2006).
Lesions of acetylcholine-producing neurons in LDTg block the DA release in NAc
induced by intra-VTA neostigmine (cholinesterase inhibitor, Blaha et al., 1996). The accumbal
efflux of DA that accompanies electrical stimulation of the LDTg is also attenuated following
injection of muscarinic or nicotinic antagonists into the VTA (Forster & Blaha, 2000; Lester,
Miller, & Blaha, 2010). LDTg-induced accumbal efflux of DA is also reduced in mutant mice
with deletion of the M5 receptor (Forster, Yeomans, Takeuchi, & Blaha, 2002; Yeomans et al,
2001).
The reinforcing properties of opioids, psychostimulants and ICSS are mediated, at least
partly, by cholinergic activation of mesoaccumbal DA neurons. Acetylcholine release in the
VTA is significantly elevated by rewarding events such as intravenous cocaine selfadministration (You, Wang, Zitzman, & Wise, 2008), subcutaneous morphine injections
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(Rezayof, Nazari-Serenjeh, Zarrindast, Sepehri, & Delphi, 2007), lateral hypothalamic selfstimulation, eating, and drinking (Rada, Mark, Yeomans, & Hoebel, 2000). Although both
nicotinic and muscarinic acetylcholine receptors in the VTA mediate the rewarding effects of
cocaine, morphine and lateral hypothalamic stimulation, it appears that the muscarinic receptors
are more involved in reward processing than nicotinic receptors. Muscarinic receptors in the
VTA contribute to the increase in accumbal DA generated by systemic administration of
morphine and this increase is readily attenuated by the infusion of the non-selective muscarinic
antagonist scopolamine into VTA (Miller, Forster, Yeomans & Blaha, 2005). Blockade of
muscarinic rather than nicotinic receptors in VTA results in attenuation of the reinstatement of
cocaine seeking and VTA DA levels induced by VTA perfusion of neostigmine (You et al.,
2008), and in the attenuation of the rewarding effects of the lateral hypothalamic stimulation
(Yeomans & Baptista, 1997).

Correspondingly, infusion into the VTA of antisense

oligonucleotides targeting muscarinic M5 mRNA inhibited local M5 receptor binding and
reduced lateral hypothalamic self-stimulation (Yeomans et al., 2000). Mutant mice with deletion
of the M5 receptor exhibit reduced CPP learning with systemic injections of morphine or cocaine
(Basile et al., 2002; Fink-Jensen et al., 2003), and show reduced cocaine self-administration
(Thomsen et al., 2005).

Similarly, muscarinic receptor blockade in VTA by scopolamine

attenuates cocaine enhancement of LDTg stimulation-evoked NAc DA release in the mouse
(Lester, Miller, & Blaha, 2010). Alternately, the rewarding effects of lateral hypothalamic
stimulation are enhanced by infusion of acetylcholine into the VTA (Olds, Yuwiler, Olds, &
Yun, 1964; Redgrave & Horrell, 1976), whereas the muscarinic antagonist atropine infused into
the VTA completely blocks self-stimulation of the lateral hypothalamus (Rada et al., 2000).
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Not surprisingly, acetylcholine receptor activation within the VTA is rewarding. IntraVTA administration of carbachol supports development of CPP learning, and rats learn to selfadminister carbachol into the VTA (Ikemoto & Wise, 2002; Yeomans, Kofman, & McFarlane,
1985). These reinforcing effects of carbachol were attenuated more effectively by pre-treating
VTA with muscarinic versus nicotinic receptor antagonists.
1.5. VTA Heterogeneity
1.5.1. Reward
However, Ikemoto & Wise (2002) observed regional differences within the VTA in the
ability of carbachol to activate DAergic reward circuitry.

Specifically, administration of

carbachol into the posterior VTA (pTVA), but not the anterior VTA (aVTA), supported
development of CPP. Also, rats learned to self-administer carbachol into the pVTA, but not into
the aVTA (Ikemoto & Wise, 2002). Similarly, rats learn to self-administer opiates (Zangen,
Ikemoto, Zadina, & Wise, 2002), cocaine (Rodd et al., 2005), nicotine (Ikemoto, Qin, & Liu,
2006),

ethanol

(Rodd-Henricks,

McKinzie,

Crile,

Murphy,

&

McBride,

2000),

tetrahydrocannabinol (cannabinoid agonist, Zangen, Solinas, Ikemoto, Goldberg, & Wise, 2006),
muscimol (GABAA agonist, Ikemoto, Murphy, & McBride, 1998), and CPBG (5-HT3 agonist,
Rodd et al., 2007), into the pVTA, but not the aVTA.
The functional differences observed by the self-administration and CPP studies may be
explained by differences in the efferent projections of the aVTA versus the pVTA. Namely,
Ikemoto (2007) conducted a series of comprehensive double immunostaining studies (with
tyrosine hydroxylase and fluorogold) and found that the cathecholaminergic neurons in pVTA
predominantly projects to the medial part of the NAc shell and the medial olfactory tubercle,
structures critical for mediating the rewarding effects of drugs of abuse as revealed by ICSS and
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CPP studies (Ikemoto, 2007, 2010; Ikemoto & Donahue, 2005; Ikemoto, Qin, & Liu, 2005;
Sellings, Bahamouri, McQuade, & Clarke, 2008; Sellings, McQuade, & Clarke, 2006a,b).
Alternatively, the aVTA provides little or no projections to the medial NAc shell and medial
olfactory tubercle, but instead projects to the NAc core, NAc ventral shell, lateral tubercle, and
dorsal striatum, into which application of DAergic drugs is not reinforcing (Ikemoto, 2007).
1.5.2. Affective Analgesia
Given the aforementioned heterogeneity within the VTA of carbachol to support
reinforcement, we evaluated regional differences within the VTA of carbachol to produce
affective analgesia (Schifirneţ & Borszcz, 2007; Schifirneţ, Karim, Lucas, & Borszcz, 2008).
According to Franklin’s affective analgesia hypothesis (1989, 1998), it is reasonable to infer that
if antinociception elicited by cholinergic activation of the VTA depends on activation of
mesoaccumbal reward circuitry, then this antinociceptive action should exhibit regional
differences within the VTA. Namely, the activation of the rewarding pVTA projections should
be conducive to affective analgesia, whereas the activation of the non-rewarding aVTA
projections should not produce affective analgesia.
Research in this laboratory has validated vocalization afterdischarges (VAD) as a model
of pain affect in rats. These vocalizations occur following a brief (1 s) noxious tailshock and are
spectrographically distinct from vocalizations that occur during tailshock (VDS). Systemically
administered drugs that preferentially suppress the affective reactions to pain in humans, like
morphine, fentanyl, and diazepam (Chapman & Feather, 1973; Gracely, McGrath, & Dubner,
1978; Price, Harkins, Rafii, & Price, 1986; Price, Von der Gruen, Miller, Rafii, & Price, 1985)
also preferentially suppress production of VADs (Borszcz et al., 1994; Caroll & Lim, 1960;
Hoffmeister, 1968; Levine, Feldmesser, Tecott, Gordon, & Izdebski, 1984). Damage to or drug
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treatments into forebrain sites known to contribute to the affective responses of humans to
clinical and experimental pain (e.g. amygdala, thalamus, hypothalamus, anterior cingulate gyrus
– aCC; Ballantine, Cassidy, Flanagan, & Marino, 1967; Foltz & White, 1968; Hebben, Corkin,
Eichenbaum, & Shedlack, 1985; Sano, Yoshioka, Ogashiwa, Ishijima, & Ohye, 1966; Sweet,
1980; Uematsu, Konigsmark, & Walker, 1974; Whittle & Jenkinson, 1995)) selectively suppress
the generation of VADs (Borszcz, 1999, 2006; Borszcz & Leaton, 2003; Borszcz & Streltsov,
2000; Greer, 2007; Greer, Wronkowicz, Harte, & Borszcz, 2005; Harte et al., 2000, 2005; Harte,
Hoot, & Borszcz, 2004; Harte, Spuz, Greer, & Borszcz, 2005; Hoffmeister, 1968; Kender, Harte,
Munn, & Borszcz, 2008; Munn & Borszcz, 2002; Munn, Harte, Lagman, & Borszcz, 2009;
Nandigama & Borszcz, 2003).

Additionally, the capacity of tailshock to support fear

conditioning in the rat relies on its capacity to elicit VADs (Borszcz, 1993, 1995, 2006, Borszcz
& Leaton, 2003). Besides the VAD model, there are virtually no animal pain models that can
directly quantify the innate, unconditional, affective reaction to pain.
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Figure 3. Affective analgesia assessment. Top. The animal is restrained on a Plexiglas
pedestal in a custom made Velcro® body suit. The electric shock is delivered via two electrodes
attached to the tail and the subsequent tail-flicks and vocalizations are recorded by a computer.
Bottom. Oscilloscope traces depicting the recorded behaviors. The top line represents the output
of the microphone, the middle line represents the duration of the shock, and the bottom line
represents the output of the displacement transducer. Note the initiation of VADs immediately
after the shock. For a complete description of the test, see Schifirneţ (2009).
Consistent with our previous report (Kender et al., 2008), administration of carbachol into
the pVTA produced dose-dependent elevation of the current thresholds for tailshock to elicit
VAD and VDS with the effect greater for VAD threshold. Alternately, the current intensity to
elicit spinal motor reflexes (SMR = tail flick and hindlimb flexion) was not altered by injection
of carbachol into the pVTA. This affective analgesia was mediated by muscarinic receptors as it
was effectively blocked by pretreating the VTA with the muscarinic receptor antagonist atropine
but not with the nicotinic receptor antagonist mecamylamine. Administration of carbachol into
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the aVTA also preferentially elevated VAD threshold that was blocked by administration of
either atropine or mecamylamine (Schifirneţ et. al, 2008). These results indicate that carbacholinduced affective analgesia relies on the activation of muscarinic receptors in pVTA and
muscarinic and nicotinic activation in aVTA.
Furthermore, during the course of this study we observed that administration of carbachol
in the area between aVTA and pVTA was ineffective in producing antinociception.

This

intermediate area of the VTA had previously not been identified as a functionally separate region
of the VTA, and we labeled it as the midVTA (Fig. 4).

Figure 4. Carbachol induces affective analgesia in aVTA and pVTA, but not midVTA.
Top. Unilateral administration of carbachol (4 µg) into the midVTA (yellow) failed to elevate
VAD thresholds as compared with the same dose administered in aVTA and pVTA (red) or with
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saline (blue). * Thresholds significantly elevated compared to saline, p < .05. Bottom. Coronal
slices representing aVTA, midVTA, and pVTA, respectively.
Taken together, the aforementioned results point to a discrepancy between the ability of
carbachol to produce reward and to induce affective analgesia, at least in the aVTA. Therefore,
this study re-assessed the ability of carbachol to support CPP in the three subregions of the VTA
using a carbachol dose that induces affective analgesia (i.e. 4 μg). Additionally, the carbacholinduced affective analgesia in the Schifirneţ et al. (2008) study relied on the activation of
muscarinic receptors in pVTA and muscarinic and nicotinic activation in a VTA as shown by the
fact that administration of atropine in the pVTA and administration of both atropine and
mecamylamine in the aVTA attenuated carbachol-induced affective analgesia. Thus, the present
study also assessed the differential involvement of muscarinic and nicotinic receptors in
activating the reward brain circuitry in the VTA subregions by pretreating the VTA with the
same doses of atropine (i.e., 60 μg) and mecamylamine (i.e., 45 μg) that proved efficacious in
attenuating the carbachol-induced affective analgesia.
Finally, the distinction between the three subregions of the VTA in the rostro-caudal axis
relies on functional findings, and not on anatomical landmarks. From a stereological point of
view, the main VTA zones rich in DA-producing neurons are paranigral nucleus (PN) and
parabrachial pigmented nucleus (PBN; Ikemoto, 2007; Nair-Roberts et al., 2008). However,
from an anatomical standpoint, the VTA is an area whose borders and components are still a
matter of debate (for an extensive review regarding VTA nuclei nomenclature, division, and
projections, see Ikemoto, 2007). For example, the 4th edition of Paxinos & Watson’s rat brain
atlas (1998) is markedly different than the 6th edition of the same atlas (2007). These differences
are to be seen both at the level of aVTA and pVTA (Fig. 5), making difficult the identification of
accurate stereotaxic coordinates. Therefore, a tyrosine hydroxylase immunohistochemistry (TH
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IHC) study was conducted in order to identify the cells that produce cathecholamines and, thus,
properly adjust the coordinates for the stereotaxic surgeries (see Methods).

Figure 5. VTA heterogeneity. Excerpts from Paxinos and Watson 4th edition (left) and 6th
edition (right) rat brain atlases showing coronal sections through the right midbrain of the rat.
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Top. Section at - 4.80 mm posterior to Bregma from the 4th edition (A) and 6th edition (B), at the
level of the putative aVTA. Note that at the same coordinates (DV=8.2mm, ML=1mm) the
atlases point to two different structures, LH and VTAR, respectively. Bottom. Sections at
approx. - 6.00 mm posterior to Bregma, from the 4th edition (C) and 6th edition (D) at the level
of the putative pVTA. Note the differences in coordinates for the PBP. Abbreviations: fr,
fasciculus retroflexus; IF, interfascicular nucleus; IPR, interpeduncular nucleus, rostral
subnucleus; LH, lateral hypothalamic area; ml, medial lemniscus; mp, mammillary peduncle;
PBP, parabrachial pigmented nucleus; pc, posterior commissure; PIF, parainterfascicular nucleus
of the VTA; PN, paranigral nucleus of the VTA; pr, prerubral field; RMC, red nucleus,
magnocellular part; RPC, red nucleus, parvocellular part; SNCD, substantia nigra, compact part,
dorsal tier; SNCM (SNM), substantia nigra, compact part, medial tier; SNR, substantia nigra,
reticular part; SuML, supramammillary nucleus (lateral part); tth, trigeminothalamic tract; VTA,
ventral tegmental area; VTAR, ventral tegmental area, rostral part (aVTA).
1.6. Behavioral Assessment
Introduced in the 1940s and then refined almost two decades later, the conditioned place
preference (CPP) paradigm is a validated experimental protocol for measuring drug reward (for
reviews, see Bardo and Bevins, 2000; McBride, Murphy, & Ikemoto, 1999; Tzschentke, 1998,
2000). “Animals, just like humans, prefer and approach environments that have been repeatedly
paired to stimuli with positive motivational properties” (DiChiara, 2000, p. 299). The conceptual
framework of the CPP paradigm is based on classical (Pavlovian) conditioning learning theory.
Namely, “the primary motivational properties of a drug or non-drug treatment serve as an
unconditioned stimulus (US) that is repeatedly paired with a previously neutral set of
environmental stimuli which acquire, in the course of conditioning, secondary motivational
properties such that they can act as conditioned stimuli (CS) which can elicit approach (or
withdrawal, if the primary motivational properties of the treatment were aversive) when the
animal is subsequently exposed to these stimuli” (Tzschentke, 1998, p. 616). Although there are
ardent debates regarding the extent of the isomorphism between the reward processes underlying
CPP and the reinforcement processes underlying self-administration, the majority of researchers
agree that, as compared with the self-administration paradigm, the CPP is more sensitive to the

21
natural state of the organism, because the testing session in the latter protocol occurs when the
animal is in a drug-free state (Bardo & Bevins, 2000).
As mentioned earlier, several classes of drugs of abuse act as DA agonists as they
increase the DA availability in the brain either by acting directly on the VTA neurons (e.g.
opioids, nicotine, ethanol) or by blocking the DA transporter or the DA D2 autoreceptor (e.g.
amphetamine, cocaine). Most DA agonists strongly support the formation of CPP, effect that is
readily blocked by administering DA antagonists (for a cross-indexed bibliography of these and
other related studies that used CPP from 1957 to 1996, see Schechter & Calcagnetti, 1993,
1998). Consequently, it is of no surprise that CPP is robustly induced by drugs of abuse like
morphine (Mueller, Perdikaris, & Stewart, 2002), heroin (Hand, Stinus, & Le Moal, 1989),
amphetamine (Spyraki, Fibiger, & Phillips, 1982), cocaine (Spyraki, Nomikos, & Varonos,
1987), nicotine (Yararbas, Keser, Kanit, Pogun, 2010), and ethanol (Gremel & Cunningham,
2008), effects that are prevented by administration of

DA antagonists (for morphine,

Manzanedo, Aguilar, Rodríguez-Arias & Miñarro, 2001; for nicotine, Acquas, Carboni, Leone,
& Di Chiara, 1989, for amphetamine, Liao, 2008, for heroin, Spyraki, Fibiger, & Phillips, 1983;
for cocaine, Bilsky, Montegut, Nichols, & Reid, 1998; for ethanol, Walker & Ettenberg, 2007).
1.7. Specific Aims:
•

Evaluate the ability of carbachol to support CPP learning in aVTA, midVTA and pVTA.

•

Evaluate the pharmacological specificity of carbachol effects by challenging CPP
acquisition with nicotinic and muscarinic antagonists.

•

Identify the location of cathecholaminergic cells within VTA in the Long-Evans rat via
TH staining.
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•

Compare across VTA subregions the ability of carbachol to induce CPP with our
previous findings of its capacity to elicit affective analgesia.
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CHAPTER 2. METHODS
2.1. Animals
Seventy-six naïve male Long-Evans rats were housed as pairs in plastic cages and given
ad libidum access to food and water. Housing was provided in a climate-controlled vivarium
maintained on a 12:12-hr circadian cycle with lights on at 0700 hrs. All testing was conducted
between 0800 and 1700 hrs. Rats were handled every three days for at least one week before
testing to minimize possible effects of stress from human contact. Also, upon arrival, rats were
given 5-7 days of acclimatization within the new environment. All procedures in this study were
approved by the Institutional Animal Care and Use Committee (IACUC) of Wayne State
University.
2.2. Surgery
All surgeries were performed under aseptic conditions. Rats were anesthetized with
sodium pentobarbital (50mg/kg, i.p.) following pretreatment with atropine sulfate (1 mg/kg, i.p.).
For VTA implants, a stainless steel 33-gauge custom cannula was stereotaxically implanted
unilaterally (right side), according to coordinates extrapolated from the rat brain atlas of Paxinos
and Watson (1998) and to the immunohistochemistry data. The coordinates (in mm) relative to
the Bregma suture and the top of the skull were for the pVTA: AP = - 4.5, ML = + 2.5, DV = 7.3, for the midVTA: AP = - 5.0, ML = + 2.5, DV = -7.3, and for the aVTA: AP = - 5.5, ML = +
2.5, DV = -7.3. Guides were affixed to the skull with 4 stainless steel bone and cranioplastic
cement. Each guide cannula was fitted with a 28-gauge dummy cannula that extended the length
of the guide to keep it clear and free of debris. Rats were given 7-10 days to recover before the
initiation of testing.
2.3. Apparatus
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The place conditioning apparatus consisted of two dimly-lit Plexiglas chambers (43 cm
long X 21.5 cm wide X 30.5 cm high) separated by an opaque black wall with a guillotine door
in the middle (8 cm wide). One chamber differed from the other by wall pattern (horizontal vs.
vertical black and whites line, each 2.5 cm wide) and floor type (horizontal vs. vertical bars).
Each chamber was equipped with four horizontal photobeam arrays: two arrays were mounted on
the each of longer sides at a height of 4.5 cm and two arrays were mounted on the longer side
opposed to the guillotine wall, at a height of 4.5 cm and 12 cm, respectively. Each photobeam
array was spaced by 2.5 cm from one another (Fig. 6).

Figure 6. The CPP apparatus. One chamber differed from the other by wall pattern
(horizontal vs. vertical black and white lines, each 2.5 cm wide) and floor type (horizontal vs.
vertical bars).
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2.4. Procedure
2.4.1. Conditioned Place Preference
Each experiment consisted of three sessions (Fig. 7): habituation (day 1), conditioning
(days 2 to 7), and testing (day 8). On Day 1, the Habituation day, the guillotine door was open
and the animals in a drug-free state were given free access to both chambers for 15 minutes. As
our dependent measure, we recorded the amount of time each rat spent in each chamber. In
order to minimize novelty effects and to ensure that rats had equal access to both chambers, each
animal was placed in front of the opened guillotine door, facing the opposite chamber. On the
first day of Conditioning, the rats received either saline or carbachol and were immediately
confined to one chamber for 15 min. The guillotine door was closed. The next day, rats were
administered the opposite drug and restricted to the opposite chamber for 15 minutes. This
procedure was repeated for the remaining days of the conditioning session. Thus, each rat was
exposed to each chamber three times, in an alternate fashion. On Day 8, the Test day, each rat
was placed in the opposite chamber than on day 1, facing the opened guillotine door. Rats had
access to both chambers for 15 min in a drug-free state and the time spent in each chamber was
recorded.
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Figure 7. The CPP timeline. The experimental design permitted the alternation of the chamber
(half of the rats received the drug in chamber A and the other half in chamber B) and order (half
of the rats received the drug first and the other half received the saline first).
After each rat exposure, the chambers were cleaned with 0.75 % Alconox (VWR) and
then aerated with Nilotron (Nilodor, Inc.) to eliminate odors from other rats. The temporal data
and other behavioral variables (e.g. locomotion, velocity, distance travelled, etc.) were recorded
each day with the aid of the Activity Monitor software, version 5 (MED Associates, Inc.).
2.4.2. Experiment 1: Carbachol-Induced CPP Learning
During CPP conditioning sessions, three groups of rats with cannulation targeting aVTA,
midVTA, or pVTA received unilateral (right) microinjections of 4 µg/.25 µl carbachol or vehicle
solution (normal saline - Sal) into the VTA on alternate days and were then immediately placed
into the CPP apparatus. Each group contained 7-8 rats.
2.4.3. Experiment 2: Antagonism Analyses
To evaluate the pharmacological specificity of carbachol, four groups of rats with
cannulations targeting aVTA and pVTA, respectively, received unilateral (right) microinjections
of either a muscarinic or nicotinic antagonist 7-10 min prior to carbachol administration. Every
animal in the muscarinic antagonism group received unilateral injections of Sal + Sal or 60 µg
atropine + 4 µg carbachol on alternate conditioning days; whereas, every animal in the nicotinic
antagonism group received unilateral injections of Sal + Sal or 45 µg mecamylamine + 4µg
carbachol on alternate conditioning days. All injections were made in a constant volume of .25
µl. Each group of animals contained 6-9 rats. As midVTA injections of carbachol failed to
support CPP, an antagonism analysis could not be conducted.
2.4.4. Drug Injections
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Intracerebral injectors targeted at the VTA extended 1.7 mm beyond the end of the
cannula. All injections were administered in a constant volume of 0.25 µl via a 33-gauge
injector. All injections were made at a constant rate over 1 min, via an infusion pump (Harvard
Model PHD 2000), and injectors were left in place for 2 min after the completion of injections to
aid in the diffusion of drugs into the tissue. Carbachol, atropine, and mecamylamine were
dissolved in normal sterile saline solution. Carbamoylcholine chloride (carbachol), Atropine
sulfate (atropine), and Mecamylamine hydrochloride (mecamylamine) were purchased from a
local branch of Sigma-Aldrich.
2.4.5. TH Immunocytochemistry and Histology
Unless otherwise specified, all chemicals were purchased from a local branch of SigmaAldrich or Fisher. TH immunoreactivity was conducted in order to localize cathecholaminergic
cells. Under deep anesthesia (150 mg/kg pentrobarbital), the animals (n = 8) were transcardially
perfused with saline solution followed by a solution of 4% paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4. After perfusion, the brains were removed from the skulls and post-fixed in the
same solution at room temperature for 3 h. Brains were then placed in sugar buffered formalin
and stored at 4°C until sectioned. For each brain, serial coronal slices (45 µm) were obtained on
a freezing microtome (Leica SM2000R) and placed in 24-free floating well plates containing 1
ml 0.1M phosphate buffered saline (PBS) at pH 7.4. The following steps were similar with the
Xavier et al. (2005) protocol and were performed at room temperature with medium agitation,
unless otherwise noted. The free-floating sections were pretreated with 1 ml of 0.3% H2O2 in
0.1M PBS for 30 min, washed three times with 1 ml of 0.1M PBS, and blocked with 500 µl of
Blocking Buffer (BB) for 60 min, containing 1% Normal Goat Serum, 1% bovine serum
albumin, 0.3% Triton X-100, in 0.1M PBS solution. The sections were then incubated over night
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with 200 µl of monoclonal tyrosine hydroxylase primary antibody raised in mice (Sigma),
diluted 1:750 in BB. After washing three times with 1 ml of 0.01M PBST (PBS mixed with
0.02% Triton X-100), the sections were incubated for 120 min. in 200 µl secondary antibody,
prediluted, biotynilated, raised in goats (Chemicon). Sections were washed again three times
with PBST and incubated for 60 min. with 200 µl Avidin-Biotin complex (Vector laboratories).
Slices then were rinsed three times in 1 ml of PBST and two times in 1 ml of 0.01M Tris-HCl
solution to bring the pH of the tissue from 7.4 to 7.6. The immunoreaction was developed by
incubating each section for 5 min in a 100ul diaminobenzene (DAB, Sigma) medium with nickel
intensification (1 pellet DAB dissolved in 5 ml of distilled H20 containing 60 mg Nickel
Ammonium Sulfate). The last step of the immunoreaction was completed by adding 100 µl of
peroxidated DAB (1 µl of 30% H2O2 to 2.5 ml DAB medium) to the sections and then quickly
removing the solution and stopping the reaction with 1 ml 0.05 Tris-HCl. Finally, the sections
were rinsed in distilled H2O, mounted on microscope gelatin-coated glass slides out of 0.01M
PBS, dehydrated in ethanol (70%, 95%, 100%, 100%; 2 min each), cleared with CitriSolv™
(Fisher) and xylene and then covered with Permount® (Fisher) and coverslips.
Rats that did not undergo TH immunohistochemistry were euthanized by carbon dioxide
asphyxiation. The injection sites were marked by an injection of 0.25 µl of safrin-O dye (EM
Science). The safranin-O injection was performed in the same fashion as the drug injections.
Brains were extracted and placed in 20% (w/v) sucrose formalin solution for 48-72 hours.
Brains were then sectioned in slices of 45 μm thickness on a freezing microtome, and injection
sites were localized with the aid of the Paxinos and Watson (1998, 2007) brain atlases and of the
TH data by two experimenters, one of whom was unaware of the behavioral outcomes.
2.5. Data analyses
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Rats that did not complete the experiment due to unforeseen circumstances (illness,
blocked cannulae, n = 3) were excluded from the data analyses. Statistically, CPP was defined
as significantly more time spent in the drug-paired compartment following conditioning sessions
(Test Day) compared to prior to conditioning (Habituation Day). Accordingly, significant effects
of treatment were determined by paired-sample Student’s t-tests for each VTA region. The
significance threshold alpha was set at .05. Statistical analyses were performed using SPSS.
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CHAPTER 3. RESULTS
3.1. Behavioral Profile
In most of the rats, carbachol injections did not change the observable immediate
behavior. However, a minority of the animals displayed either hyperactivity (e.g., ipsilateral
rotation, increased grooming hyperlocomotion, increased exploration and rearing) or
hypoactivity (very calm, almost immobile, with eyes half-closed) both during carbachol injection
and diffusion. These behavioral effects were not consistent in the same animal (i.e. did not
exhibit the behavioral profile following every injection) and a particular profile was not
restricted to a particular VTA subregion.
3.2. Initial Chamber Preference
Rats were tested using an unbiased procedure in a two chamber CPP apparatus (see
Methods for details of training and microinjection procedures). Because there are reports that
rats may have an initial tendency to prefer one of the two chambers (for a discussion on this
methodological issue, see Bardo & Bevins, 2000, p. 38), a comparison of the amount of time
spent in each chamber on the Habituation Day was conducted. Collapsing data across all groups,
rats initially spent an equal amount of time in each chamber (t(56) = .39, p > .05), indicating
that an initial chamber preference did not confound the results of CPP training (Fig. 8).
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Figure 8. Animals did not exhibit any tendency to prefer one chamber vs. another prior to
conditioning. The rats spent almost exactly equal amount of time in each chamber.
3.3. Experiment 1: Carbachol-Induced CPP Learning
Unilateral administration of carbachol (4μg in .25μl) into either the pVTA (Fig. 9) or
aVTA (Fig. 10) was effective in supporting CPP learning. The amount of time spent in the
carbachol-paired chamber was directly compared before and after the conditioning took place.
Rats spent significantly more time in the carbachol-paired compartment after conditioning
(pVTA: t(6) = 3.98, p < .01; aVTA: t(5) = 4.04, p = .01).
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Figure 9. Unilateral administration of carbachol into pVTA produces CPP. *Significantly
more time spent in the carbachol paired compartment after vs. before conditioning, p < .01.

Figure 10. Unilateral administration of carbachol into aVTA produces CPP. *Significantly
more time spent in the carbachol paired compartment after vs. before conditioning, p = .01.
Alternately, unilateral administration of carbachol (4μg in .25μl) into the midVTA failed
to support CPP learning (Fig. 11). There was no significant difference between the time spent in
the carbachol-paired compartment before and after conditioning (t(7) = .22, p > .05).
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Figure 11. Unilateral administration of carbachol into the midVTA does not produce CPP.
Note that the rats spent almost the exact amount of time in both chambers after conditioning.
3.4. Locomotion
The behavioral effects observed in some rats following injection of carbachol were not
observed on conditioning days when rats received vehicle injections or on the Test Day when no
injections were administered. Nevertheless, possible confounding effects of carbachol-induced
locomotion during the Test Day were assessed (Fig. 12). The level of locomotor activity
(defined as number of photobeam breaks) prior to carbachol treatment (Habituation Day) was
compared to that observed during the Test Day. No difference in locomotion was observed in
groups administered carbachol into the aVTA or midVTA (t(5) = .50, p > .05 and t(7) = 1.14, p >
.05, respectively). However, rats that received carbachol in the pVTA during conditioning
exhibited elevated locomotion during the Testing Day (t(6) = 3.36, p < .05).
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Figure 12. Carbachol-induced locomotor activity. * Significantly more photobeam breaks
during the Testing (T) Day compared with the Habituation (H) Day, p < .05.
As depicted in Fig. 13, rats that received carbachol in the pVTA also exhibited an
increased number of chamber crossing during the Test Day as compared to the Habituation Day
(t(6) = 2.49, p = .05). No difference in the number of chamber crossing was observed in rats that
were administered carbachol into aVTA or midVTA (t(5) = 1.65, p > .05 and midVTA, t(7) =
1.87, p > .05, respectively).

Figure 13. Carbachol-induced zone crossings. * Significantly more chamber crossings during
the Testing (T) Day compared with the Habituation (H) Day, p = .05.
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It is unlikely that the CPP learning observed by the group administered carbachol into
pVTA is confounded by the increased locomotor activity and chamber crossing observed during
the Test Day. Despite increased sampling of both chambers this group spent significantly more
time in the carbachol-paired chamber. Typically, it is a decrease in locomotor activity and
chamber crossings that is suspected as confounding chamber preference during the Test Day, i.e.
“the higher the rate of locomotion in one compartment relative to the other, the greater is the
probability that the rat will leave that compartment” (Martin-Iverson, Reimer, & Sharma, 1997,
p. 328).
3.5. Experiment 2: Antagonism Analysis
The pharmacological specificity of carbachol-induced CPP was evaluated by pretreating
the VTA with muscarinic (atropine) or nicotinic (mecamylamine) antagonists prior to carbachol
administration.
3.5.1. Muscarinic Receptors
Unilateral administration of atropine (60 μg in .25μl) prior to carbachol (4μg in .25μl)
injections into either the pVTA (Fig. 14) or aVTA (Fig. 15) prevented the development of
carbachol-induced CPP learning. The amount of time spent in the drug-paired chamber was
directly compared before (Habituation Day) and after (Test Day) the conditioning took place.
There was no significant difference between the amount of time the animals spent in the atropine
+ carbachol paired chamber and the saline + saline compartment after conditioning when the
drugs were administered in pVTA (t(5) = .22, p > .05). The rats that received the atropine +
carbachol treatment in aVTA spent less time in the drug-paired compartment than in the vehiclepaired compartment after conditioning (t(8) = 2.94, p < .05).
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Figure 14. Muscarinic mediation of CPP in pVTA. Atropine pretreatment prevented the
formation of carbachol-induced CPP. Legend: Atr = atropine, Carb = carbachol, Sal = saline.

Figure 15. Muscarinic mediation of CPP in aVTA. Atropine pretreatment prevented the
formation of carbachol-induced CPP. # Significantly less time spent in the drug-paired
compartment after vs. before conditioning, p < .05. Legend: Atr = atropine, Carb = carbachol,
Sal = saline.
3.5.2. Nicotinic Receptors
Unilateral administration of mecamylamine (45 μg in .25μl) prior to carbachol (4 μg in
.25 μl) injections into either the pVTA (Fig. 16) or aVTA (Fig. 17) prevented the development of
carbachol-induced CPP learning. The amount of time spent in the drug-paired chamber was
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directly compared before (Habituation Day) and after (Test Day) the conditioning took place.
There was no significant difference between the amount of time the animals spent in the
mecamylamine + carbachol paired chamber and the saline + saline compartment after
conditioning (pVTA: t(5) = 1.77, p > .05; aVTA: t(6) = .99, p > .05).

Figure 16. Nicotinic mediation of CPP in pVTA. Mecamylamine pretreatment in pVTA
prevented the formation of carbachol-induced CPP. Legend: Carb = carbachol, Mec =
mecamylamine, Sal = saline.

Figure 17. Nicotinic mediation of CPP in aVTA. Mecamylamine pretreatment in pVTA
prevented the formation of carbachol-induced CPP. Legend: Carb = carbachol, Mec =
mecamylamine, Sal = saline.
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3.6. Tyrosine Hydroxylase Immunohistochemistry
Figure 18 shows the localization of catecholamine producing neurons within aVTA (top),
midVTA (middle) and pVTA (bottom) of the intact adult male Long-Evans rat.

Surgery

coordinates for CPP studies were adjusted accordingly. See Methods for experimental details.

Figure 18. Catecholamine-producing neurons within VTA. Top. aVTA. Middle. midVTA.
Bottom. pVTA. The staining was obtained via TH IHC.
The exact location of the injection sites performed in aVTA, midVTA, and pVTA is
shown in Fig. 19, Fig. 20, and Fig. 21, respectively.
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Figure 19. Coronal diagrams extracted from Paxinos and Watson (2007) representing the
cannula placements in aVTA. The red circles represent the location of the 4 μg carbachol
microinjections and the blue squares represent the location of either 60 μg atropine + 4 μg
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carbachol or 45 mecamylamine + 4 μg carbachol microinjections. Numbers on the right side of
diagrams represent coordinates in millimeters posterior to Bregma.

Figure 20. Coronal diagrams extracted from Paxinos and Watson (2007) representing the
cannula placements in midVTA. The black triangles represent the location of the 4 μg
carbachol microinjections. Numbers on the right side of diagrams represent coordinates in
millimeters posterior to Bregma.
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Figure 21. Coronal diagrams extracted from Paxinos and Watson (2007) representing the
cannula placements in pVTA. The red circles represent the location of the 4 μg carbachol
micro injections and the blue squares represent the location of either 60 μg atropine + 4 μg
carbachol or 45 mecamylamine + 4 µg carbachol microinjections. Numbers on the right side of
diagrams represent coordinates in millimeters posterior to Bregma.
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3.7. Comparison between Carbachol-Induced Affective Analgesia and Reward
Figure 22 compares the capacity of 4 µg carbachol administered into subregions of the
VTA to support CPP learning (present study) and generate increases in VAD threshold
(Schifirneţ & Borszcz, 2007). The capacity of carbachol to elevate VAD threshold depended on
the subregion of the VTA into which carbachol was injected. Comparison of VAD thresholds
following injection of carbachol into the aVTA, midVTA and pVTA revealed significant
differences (F(2,40) = 46.4, p < .001). Planned pairwise comparisons revealed that the mean
threshold current intensity necessary to elicit VAD was significantly lower when the drug was
delivered into the midVTA compared with aVTA (t(23) = 8.91, p < .001) and pVTA (t(25) =
10.08, p < .01). Comparison between 4 μg carbachol treatment in aVTA and pVTA indicated no
difference in the VAD threshold (t(32) = .65, p = .52).
Similarly, analysis of the groups of animals that received unilateral 4 µg carbachol
injections in the aVTA, midVTA, and pVTA in the present study revealed that the CPP score is
significantly affected by the region into which the drug is delivered (F(2,18) = 7.32, p = .005).
The CPP score is defined as time spent in the carbachol-paired chamber after conditioning minus
time spent in the carbachol-paired chamber before conditioning. Specifically, direct planned
comparisons revealed that the animals spent significantly less amount of time in the drug-paired
chamber when the drug was delivered into the midVTA compared with aVTA (t(12) = 3.36, p <
.01) and pVTA (t(13) = 3.31, p < .01). Comparisons between 4 μg carbachol treatment in aVTA
and pVTA indicated no difference in the CPP score (t(11) = .03, p = .98).
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Figure 22. Unilateral 4 µg carbachol injections support the development of CPP learning
and affective analgesia in both the aVTA and pVTA, but not in the midVTA. Top left.
Carbachol (4 µg) administered in mid-VTA (black) failed to elevate VAD thresholds as
compared with the same dose administered in aVTA and pVTA (red). * Thresholds significantly
elevated compared to midVTA, p < .01. Top right. Carbachol (4 µg) administered aVTA and
pVTA (red), but not in mid-VTA (black) supported the acquisition of CPP learning in mid-VTA
(black). * CPP score significantly elevated compared to midVTA, p < .01. Bottom. Coronal
slices representing the aVTA, midVTA, and pVTA, respectively, from the Schifirneţ & Borszcz
(2007) study (left) and from the present study (right).
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CHAPTER 4. DISCUSSION
This study is the first to directly compare the extent of overlap between cholinergically
mediated reward and affective analgesia within different VTA regions. We tested Franklin’s
(1989, 1998) analgesia hypothesis that postulated that activation of the brain reward circuit
should be conducive to affective analgesia Our data indicate that unilateral 4 µg carbachol
injections support both the development of CPP learning and affective analgesia in both the
aVTA and pVTA, but not in the midVTA (Fig. 22), supporting the affective analgesia
hypothesis. However, the extent of overlap between the neural circuits underlying affective
analgesia and reward is only partial, as different cholinergic receptors are responsible for these
effects in different subregions of the VTA. Whereas both nicotinic and muscarinic receptors
contribute to carbachol-induced affective analgesia aVTA, as shown by the ability of both
atropine and mecamylamine to reduce the carbachol-induced increases in VAD threshold, only
the muscarinic receptors are mediating the analgesic action of carbachol in the pVTA, because
mecamylamine was ineffective in attenuating the carbachol analgesia, but atropine reliably
blocked this effect. On the other hand, the rewarding effects of carbachol are mediated by the
activation of both nicotinic and muscarinic receptors in both aVTA and pVTA, as indicated by
the fact that both atropine and mecamylamine prevented the development of CPP in both VTA
subregions.
4.1. Differential Cholinergic Activation of the VTA in Reward and Analgesia
Two previous studies addressed the rewarding properties of intra-VTA carbachol
administration by employing the CPP paradigm. The first study observed that carbachol (0.5 µg
and 2 µg/side) is reinforcing in the VTA (Yeomans et al., 1985). Yet, in this study, different
VTA subregions were not assessed, as the cannulae placements ranged from - 4.8 mm to - 6.3
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mm from Bregma, covering the majority of the VTA. The second study conducted by Ikemoto
& Wise (2002) evaluated the capacity of carbachol to support CPP in the aVTA and pVTA and
found that carbachol supports CPP learning only in the pVTA. Nevertheless, this study used
significantly lower doses of carbachol (ranging from 0.00546 µg to 0.091 µg) as compared with
our doses that proved efficacious in inducing affective analgesia (2 and 4 µg). At the lowest
dose (1 µg) used in the Schifirneţ & Borszcz (2007) study, carbachol failed to induce affective
analgesia in any VTA subregion. Therefore, it is possible that low doses (0.09 µg) of carbachol
are not rewarding, but the high dose (4 µg) used in this study are able to induce CPP in the
aVTA.
When 4 µg carbachol was administered in the midVTA, as opposed to the aVTA or
pVTA, it failed to induce either affective analgesia or reward, suggesting that carbachol-induced
CPP is anatomically specific to the aVTA and pVTA. To the best of my knowledge, there is
only one study published to date that found an anterior-posterior bimodal activation within the
VTA. Marcangione & Rompré (2008) trained rats to self-administer electrical stimulation to the
posterior mesenchephalon and assessed the subsequent c-Fos expression within VTA. The
authors found that in both the aVTA and pVTA there was an increase in the c-fos expression
following posterior mesenchephalon stimulation, but the lateral midVTA exhibited the lowest
number of Fos-positive cells. The fact that the midVTA is not involved in the rewarding effects
of posterior mesenchephalon self-stimulation (Marcangione & Rompré, 2008) or in the
locomotor (Museo & Wise, 1995) and rewarding effects of cytisine 4 (R. A. Wise, personal
communication, 6/17/2010) indicates that unlike the aVTA and pVTA, the activation of the
midVTA is not reinforcing.

4

Taken together, and concordant with the affective analgesia

Cytisine is a nicotinic agonist that supports the development of CPP when delivered into the aVTA (Museo &
Wise, 1994)
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hypothesis, these results suggest that there is a similar regional heterogeneity within the VTA
mediating analgesia and reward: wherever carbachol is reinforcing within the VTA, it also
produces affective analgesia; conversely, wherever in the VTA carbachol injections are not
reinforcing, this drug also fails to induce affective analgesia.
The carbachol-induced affective analgesia and reward in the aVTA and pVTA is thought
to be mediated by its binding to the muscarinic and nicotinic receptors located on the
dopaminergic neurons within the VTA. Thus, carbachol activation of the dopaminergic neurons
mimics the actions of acetylcholine release from the LTDg and PPTg nuclei 5 , resulting in
subsequent dopamine release into the terminal VTA efferent sites. As stated above, cholinergic
activation of the VTA following electrical stimulation of LTDg (Forster & Blaha, 2000; Forster
et al., 2002; Yeomans et al., 2001) or intra-VTA administration of cholinergic agonists, like
carbachol (Westerink et al., 1996), oxotremorine M (muscarinic agonist, Gronier & Rasmussen,
2000), or nicotine (Blaha et al., 1996) results in increased accumbal DA efflux.

This

cholinergically mediated DA release into the NAc is reinforcing as it is associated with the
rewarding effects of morphine (Rezayof et al., 2007), cocaine (You et al., 2008), and lateral
hypothalamic self-stimulation (Rada et al., 2000).
Activation of muscarinic rather than nicotinic receptors seems to be more involved in
reward processing (Yeomans & Baptista, 1997, You et al., 2008). Both the increase in accumbal
DA release and the rewarding effects associated with morphine injections (Miller et al., 2005),
cocaine self-administration (You et al., 2008), lateral hypothalamic stimulation (Rada et al.,
2000; Yeomans & Baptista, 1997; Yeomans et al., 2000) are blocked more by pretreating the

5

These cholinergic structures that project to the VTA are also involved in noxious (LDTg, Kayama & Ogawa, 1987;
PPTg, Carlson et al., 2004; Iwamoto, 1991; Kayalioglu & Balkan, 2004) and reward – related (LDTg, Nakahara,
Ishida, Nakamura, Furuno, & Nishimori, 2001; PPTg, Okada, Toyama, Inoue, Isa, & Kobayashi, 2009; Olmstead,
Munn, Franklin, & Wise, 1998) information processing.

47
VTA with muscarinic rather than nicotinic antagonists. In concordance with this, our study
found that the VTA muscarinic receptors mediate the rewarding and analgesic effects of
carbachol, as atropine blocked the carbachol-induced CPP and affective analgesia in both the
aVTA and pVTA.
Although not to the same extent as muscarinic receptors, the activation of the nicotinic
receptors from the VTA is also reinforcing. Knock-out mice with deletion of nicotinic receptor
genes that underwent viral restoration of the nicotinic receptors α4β2 and α6β2 selectively in the
VTA self-administer i.v. nicotine, but not if these receptors are missing from the VTA or are
restored elsewhere in the brain (Pons et al., 2008), suggesting that these particular nicotinic
subtypes expressed onto the DA neurons are necessary and sufficient for nicotine selfadministration. Nicotinic activation of the VTA DA neurons results in increased DA accumbal
efflux (Cadoni, Muto, Di Chiara, 2009; Yoshida et al., 1993; Zhang et al., 2009) and this efflux
is blocked by intra-VTA application of nicotinic antagonists (Gotti et al., 2010; Nissel et al.,
1994). The reinforcing properties of nicotine depend on the integrity of mesoaccumbal DA
terminals, as shown by the fact that nicotine self-administration is reduced in rats with intra-NAc
6-OHDA lesions 6 (Corrigall, Franklin, Coen, & Clarke, 1992).

Alternately, intra-VTA

microinjection of the nicotinic antagonist DHβE attenuates i.v. nicotine self-administration
behavior (Corrigall, Coen, & Adamson, 1994). Nicotine also supports the development of CPP
(Vastola, Douglas, Varlinskaya, & Spear, 2002; Yararbas et al., 2010) and the acquisition of this
learning is blocked by intra-NAc shell D1 antagonists (Spina, Fenu, Longoni, Rivas & Di Chiara,
2006). Consistent with these findings, the results of our study revealed blockade of nicotinic
receptors by mecamylamine into either aVTA or pVTA prevents the development of carbachol6

When administered into the catecholaminergic terminal sites, like NAc, this neurotoxin is taken up by the terminal
buttons of DA axons and transmitted via retrograde transport to cell bodies in VTA where it destroys these cells by
inducing apoptosis (for a review, see Blum et al., 2001).

48
induced CPP learning.

On the other hand, mecamylamine reduced the carbachol-induced

affective analgesia only when administered into the aVTA, but not in the pVTA.
It is important to mention that administration of an antagonist prior to a non-specific
agonist is not identical to administration of the other agonist alone.

In other words,

administration of mecamylamine + carbachol does not equal administration of muscarine. If this
were true, then administration of atropine prior carbachol in our study, for example, would not
have prevented the development of CPP learning, as the activation of the nicotinic receptors
within the VTA is reinforcing.

Therefore, the present study suggests that there is a

subpopulation of muscarinically activated AND nicotinically inhibited neurons within the pVTA
that is involved in affective analgesia, but not in reward (Fig. 23). Conceivably, in order to
produce a compound that when administered into the pVTA has an analgesic, but not a
rewarding effect, this compound must be a combination of a muscarinic agonist and a nicotinic
antagonist. Thus, at least at the level of the pVTA, the neural circuits contributing to affective
analgesia and reward overlap only partially. Further studies are needed to characterize the
potential analgesic and/or rewarding effects of direct nicotinic or muscarinic activation of the
VTA by injecting nicotine or muscarine alone, without actively inhibiting the other receptors
type.
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Figure 23. The differential involvement of nicotinic and muscarinic receptors in aVTA,
midVTA, and pVTA in affective analgesia (AA) and conditioned place preference (CPP).
Note that in the pVTA there is a subpopulation of muscarinically activated AND nicotinically
inhibited neurons that is involved in affective analgesia, but not in reward.
It is possible that the differential involvement of cholinergic receptors in the three VTA
subregions in reward and analgesia relies on the different densities of nicotinic and muscarinic
receptors in these areas. Unfortunately, there is no extant evidence of the distribution of the
cholinergic receptors in these VTA subregions. Thus, future studies that perform ultrastructural
localization of the cholinergic receptors in the VTA would provide useful information that help
assess whether cholinergic receptors display a regional heterogeneity within VTA.
Another possibility is that the cholinergic agents used in this study bound to receptors
located on non-dopaminergic neurons. From a quantitative point of view, the most recent
unbiased stereological estimate of the rat VTA reports that GABA neurons constitute about 35%
of the VTA, with glutamate neurons constituting about 2-3%, and the remaining 63% (approx.
40,000 cells) being DA neurons (Nair-Roberts et al., 2008). It is important to stress that the
distribution of these three cell types is not uniform across the VTA, with more glutamate and less
GABA neurons in the aVTA and more GABA cells and almost no glutamate neurons in the
pVTA (Nair-Roberts et al., 2008; Yamaguchi, Sheen, & Morales, 2007). In addition to the VTA
neurons, en passant axons and most of the VTA terminals possess muscarinic and nicotinic
receptors (Adell & Artigas, 2004) and binding to cholinergic agents to these receptors can result
in either depolarization or hyperpolarization of VTA neurons.

For example, the nicotinic

receptor α4β2 is expressed by GABA afferents and the nicotinic receptor α7 by glutamate inputs
(Keath, Iacoviello, Barrett, Mansvelder, & McGehee, 2007). These cytoarchitectonic differences
may result in differential modulation of VTA subregions by cholinergics and, as a consequence,
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differential involvement of the VTA subregions in reward and analgesia.

Further studies

designed to identify the muscarinic and nicotinic receptor subtypes responsible for the results
obtained in this study, along with their exact location, would provide further insight into the
mechanisms of cholinergically mediated analgesia and reward.
4.2. Downstream Effects
4.2.1. Nucleus accumbens (NAc)
As mentioned earlier, previous studies suggested that the activation of the pVTA, but not
the aVTA, mediates the reinforcing effects of opiates (Zangen et al., 2002), cocaine (Rodd et al.,
2005),

nicotine

(Ikemoto,

et

al.,

2006),

ethanol

(Rodd-Henricks

et

al.,

2000),

tetrahydrocannabinol (Zangen et al., 2006), muscimol (GABAA agonist, Ikemoto et al., 1998),
CPBG (5-HT3 agonist, Rodd et al., 2007), and low doses of carbachol (Ikemoto & Wise, 2002).
These functional differences are thought to rely on the differences in efferent projections of these
two subregions: pVTA projects predominantly to limbic structures critical for reinforcement
(e.g., medial part of the NAc shell and the medial olfactory tubercle), whereas aVTA projects to
limbic regions less involved in reinforcement processes (e.g., NAc core, NAc ventral shell,
lateral tubercle, and dorsal striatum (Ikemoto, 2007, 2010).
However, besides striatum and the olfactory tubercle, the VTA sends efferents to other
subcortical structures, such as the habenula, bed nucleus of stria terminalis, amygdala,
hippocampus, and septum (for reviews, see Deniau, Thierry, & Feger, 1980; Moore & Bloom,
1978; Oades & Halliday, 1987; Swanson, 1982). Moreover, the mesocortical dopaminergic
system, comprising of the VTA’s efferents to prefrontal, insular and cingulate cortices (Fluxe et
al., 1974, Ohara et al., 2003; Williams & Goldman-Rakic, 1998), is well characterized and
heavily investigated by cognitive neuroscientists (Wise, 2004). In addition to the mesolimbic
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and mesocortical projections, VTA neurons send several sparse efferents to the adjacent
substantia nigra (Ferreira, Del-Fava, Hasue, & Shammah-Lagnado, 2008), thalamus (Beckstead,
Domesick, & Nauta, 1979), hypothalamus (Phillipson, 1979), locus coeruleus (Oades &
Halliday, 1987), dorsal raphe (Kalen, Skagerberg, & Lindvall, 1988), and periaqueductal grey
(PAG, Kirouac, Li, & Mabrouk, 2004).
As mentioned above, Ikemoto (2007) found that the pVTA predominantly projects to the
medial part of the NAc shell and the medial olfactory tubercle; in contrast, the aVTA projects
mostly to the NAc core, NAc ventral shell, lateral tubercle, and dorsal striatum. Somewhat
inconsistent findings were reported by Lammel et al. (2008) who found by retrograde tracing that
the medial VTA projects to mPFC, amygdala, NAc core and medial shell, whereas the lateral
VTA (whether posterior or anterior) projects to the NAc lateral shell (Lammel et al, 2008). Yet
other groups maintain that the medial VTA projects to the lateral habenula, locus coeruleus and
parabrachial nucleus, the dorsal VTA projects to the pregenual aCC, the ventral VTA projects to
NAc, septum, amygdala, and supragenual aCC, and the ventroanterior VTA projects to the
hippocampus and entorhinal cortex (Swanson, 1982).

Also, the anterodorsal VTA is the

predominant origin for mesocortical projections, whereas the posteroventral portion of the VTA
gives rise to the mesolimbic projections (Fluxe, et al., 1974, Oades & Halliday, 1987). With
respect to the mesocortical system, the pregenual cortex receives projections from the medial
VTA, the supragenual cortex from the ventrolateral VTA and the perirhinal cortex from the
dorsolateral VTA (Lindvall, Bjorklund, & Divac, 1978). Also, it is important to mention that the
midVTA is a region that has not yet been investigated as a separate functional subunit of the
VTA and its afferent and efferent projections are unknown.
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Inasmuch as some of the divergences in these tracing studies can be accounted for by
species differences or tracing methods, more research needs to be conducted to asses the
anatomical organization of the mesolimbic and mesocortical neurons within the VTA. Also,
there is virtually no evidence of cell distribution or afferents/efferents labeling in the midVTA.
Nevertheless, these findings indicate that 1) the subpopulations of the neurons that project to a
particular region are distributed throughout the VTA on rostro-caudal, ventro-dorsal, and mediolateral axes, and 2) the mesolimbic efferents tend to cluster more in the posterior than in the
anterior VTA, more medially than laterally, whereas the mesocortical efferents display the
opposite pattern.
Although the carbachol microinjections in both the present study and the Schifirneţ &
Borszcz (2007) study were performed in the center of the aVTA and the pVTA, and thus not
allowing a finer distinction between medial and lateral aspects of the VTA, it can be speculated
that carbachol activated most of the reward-processing clusters of mesoaccumbal neurons within
the pVTA and the aVTA, albeit there are less mesoaccumbal rewarding cell populations in the
aVTA. If the reinforcing and analgesic neural substrates within the VTA were entirely shared,
then the amplitude of the VAD thresholds increases and the magnitude of CPP score following
carbachol administration would have varied according to the distribution of the mesoaccumbal
reward populations in the pVTA and the aVTA (i.e., a slight decrease in the VAD thresholds and
CPP score in the aVTA compared with pVTA). Since there was virtually no difference between
the carbachol-induced increase in VAD thresholds and CPP score in the aVTA and the pVTA
(Fig. 20) it is concluded that the carbachol-induced affective analgesia and reward when
delivered in to the pVTA is mediated primarily by DA release in NAc. On the other hand, the
carbachol-induced affective analgesia and reward in the aVTA may rely on DA release in other
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terminal structures, presumably mesocortical. Thus, while the rewarding and analgesic effect
obtained by cholinergic activation of the pVTA may rely on activation of the mesoaccumbens
dopaminergic system, the same effects obtained in the aVTA may rely on the DA release into
structures other than NAc, like aCC, insula, or amygdala.
4.2.2. Anterior cingulate cortex (aCC)
The aCC is paramount for the generation of the affective-motivational aspect of the pain
experience, but it is not involved in the processing of the sensory-discriminative aspect (Cao et
al., 2009; Gao, et al., 2004; Johansen & Fields, 2004; Johansen, Fields, & Manning, 2001; Lei,
Sun, Gao, Zhao, & Zhang, 2004; Li et al., 2009; Ren et al., 2006; Sewards & Sewards, 2002; Sun
et al., 2008; Treede, Kenshalo, Gracely, & Jones, 1999; Vogt, 2005; Xie, Huo, & Tang, 2009),
and its activation is required for the generation of pain unpleasantness (Kulkarni et al., 2005;
Rainville, Duncan, Price, Carrier, & Bushnell, 1997; Vogt & Sikes, 2000). Moreover, surgical
cingulotomy in humans results in a pain relief that is associated with the attenuation of the pain
affect (Hassenbusch, Pillay, & Barnett, 1990; Hurt & Ballantine, 1974; Pillay & Hassenbusch,
1992; Wilson & Chang, 1974). In point of fact, in a striking similarity with the patients that
receive morphine for severe pain, the patients with cingulotomies report that the pain is still
present, but it does not bother them. The aCC receives DAergic (Oades & Halliday, 1987),
GABAergic (Carr & Sesack, 2000) and possibly glutamatergic input from the VTA (Sulzer &
Rayport, 2000; Trudeau, 2004). Stimulation of the VTA also inhibits the aCC neurons that
respond to noxious stimuli (Mantz, Milla, Glowinski, & Thierry, 1988; Pirot, Glowinski, &
Thierry, 1996). Correspondingly, microinjections of DA or DA agonists into the aCC suppress
pain behaviors associated with long-term nociception elicited by sciatic denervation in the rat
and these antinociceptive effects are blocked by microinjecting DA antagonists into the aCC
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(Lopez-Avila, Coffeen, Ortega-Legaspi, del Angel, & Pellicer, 2004). Taken together, these
findings suggest that the DAergic projection from the VTA to the aCC is essential for analgesia.
Thus, it is possible that the increase in the VAD thresholds following carbachol administration
into the aVTA observed in the Schifirneţ & Borszcz (2007) study is partially dependent on the
DA release into the aCC.
Converging evidence suggests that the aCC is a structure critical also for reward and
reinforcement. To the extent that in rat the aCC is part of the PFC (for an extensive review, see,
Uylings, Groenewegen, & Kolb, 2003), DA agonists like amphetamine and cocaine increase
extracellular DA in rat PFC and cocaine facilitates both PFC and medial forebrain bundle (MFB)
self-stimulation (Moody & Frank, 1990); this facilitation of PFC self-stimulation is completely
blocked by DA antagonists (McGregor, Atrens, & Jackson, 1992). Similarly, cocaine (Goeders
& Smith, 1983) and DA (Goeders & Smith, 1986) self-administrations into the aCC are
abolished by microinjecting D1 DA antagonists or lesioning the DA terminals in this region. In
addition, DA antagonists microinjected into the prelimbic portion of medial PFC (mPFC) block
the reinforcing effects of i.v. cocaine (McGregor & Roberts, 1995), whereas VTA lesions block
cocaine self-administration (Roberts & Koob, 1982). Normally, rats will work harder if the
reward is bigger, but not if they are given systemic D2 antagonists or if their DA terminals
within aCC are lesioned (Walton et al., 2009). Taken together, these finding suggest that the DA
input to aCC is required for drug self-administration and reward processing.

Thus, the

development of CPP following carbachol administration into the aVTA can be explained, at least
partially, by the reinforcing effects of DA release into the aCC.
4.2.3. Insula
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Another of the target structures of the VTA involved in pain processing, analgesia, and
reward is the insula. Many imaging studies have shown that insular activation is correlated with
the conscious, subjective feeling of craving or urge of taking drugs of abuse such as cocaine,
heroin, alcohol, and nicotine (for a review of these studies, see Naqvi & Bechara, 2009).
Conversely, damage to the insular cortex promotes a “disruption of smoking addiction” in
humans (Naqvi, Rudrauf, Damasio, & Bechara, 2007, p. 531), suggesting that this region plays a
central role in the initiation of drug urges.

Likewise, lidocaine inactivation of the insula

abolished the ability of amphetamine to induce CPP learning (Contreras, Ceric, & Torrealba,
2007), bringing further evidence that the “insular cortex is a key structure in the perception of
bodily needs that provides direction to motivated behaviors” (p. 655).

With respect to

reinforcement, both D1 receptor activation and inactivation in the rat dorsal agranular insular
cortex reduce the lever-pressing for cocaine, but only the D1 blockade results in a significantly
reduced amount of cocaine intake in the addicted rat (Di Pietro, Mashhoon, Heaney, Yager, &
Kantak, 2008).

Interestingly, D1 receptor blockade also disrupted the food-maintained

responding and consumption in the normal rat, suggesting that the DAergic afferents to the
insular cortex are important not only for reward processing in a dependent organism, but also for
the initiation and maintenance of the motivation to seek natural reinforcers.
Based on the observation that the insula receives ample information from the body and
thalamus about interoceptive sensations (e.g., pain, inflammation, temperature, taste, itch,
sensual touch, tickle, air hunger, visceral and muscular sensation), Craig (2002) proposed that
the primary role of the insula is to create a map of the bodily states that, together with other
structures, might constitute the “basis for human awareness of the physical self as a feeling
entity” (p. 663). According to this view, the insula is a crucial part of a system that not only
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updates the interoceptive maps based on signals from the body when something is changed, but
also makes these maps available to awareness (i.e. consciousness). These neural maps are not
devoid of meaning, since their continuous updates are necessary for the brain to maintain
homeostasis. As such, the insula, along with the amygdala, aCC, and ventromedial PFC, might
make available to consciousness emotions associated with imbalances in the bodily states, like
“urges”, “wantings”, “desires”, or what Damasio (1994) calls “somatic markers” (also, for a
discussion of the somatic-marker hypothesis, see Bechara, Damasio, & Damasio, 2000). With
respect to drugs of abuse, the insula is probably a central player in representing the interoceptive
effects of these drugs in the form of a neural map (Naqvi & Bechara, 2009). Therefore, when the
body is experiencing withdrawal symptoms, the insula translates these interoceptive signals into
a conscious, subjective feeling of “urge” to address the imbalance by taking the drug that restores
the homeostasis. Naqvi & Bechara (2009) proposed that DA release from the VTA into the
insula might contribute to the updates of the neural map from the insula about drug-induced
interoceptive changes by bringing information about the hedonic value of the drug use.
The homeostatic role of the insular cortex is also supported by pain research. Pain can be
viewed as a homeostatic emotion destined to signal the violation of the integrity of the body
(Craig, 2003), and, not surprisingly, insular activation during pain experience is the most
frequently reported finding in the imaging studies on pain processing (Apkarian, Bushnell,
Treede, & Zubieta, 2005).

Moreover, electrical stimulation of the human posterior insula

produces pain sensations like stinging, burning or disabling pain in a somatotopic fashion
(Ostrowsky et al., 2002) and the subjective intensity of pain is correlated with activation of the
insula (Coghill, Sang, Maisog, & Iadarola, 1999; Koyama, McHaffie, Laurienti, & Coghill,
2005). Alternately, patients with insular damage show absent or inadequate emotional responses
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to painful stimuli (i.e. pain asymbolia; Berthier, Starkstein, & Leiguarda, 1987; Greenspan, Lee,
& Lenz, 1999), underscoring the importance of the insula in processing the affectivemotivational aspect of pain.
Of note, the rostral agranular insular cortex (RAIC) is a region that is heavily innervated
by DAergic fibers (Jones, Kilpatrick, & Phillipson, 1986; Ohara, et al., 2003) and DA release in
the insula is essential for antinociception. Injections of the DA reuptake inhibitor GBR-12935
into the RAIC result in dose-dependant inhibition of the pain behaviors induced by formalin
inflammation that is reduced by administration of the selective D1 receptor antagonist SCH23390 into the RAIC (Burkey, Carstens, & Jasmin, 1999).

Consistent with these results,

DAergic stimulation of the insula by intra-RAIC GBR-12935 injections reduced the noxious
stimulus-induced c-fos expression in nociceptive spinal dorsal horn neurons, as well as the firing
of these neurons in response to noxious heat application to the paw, suggesting that the role of
DA release into RAIC is to inhibit nociception (Burkey et al., 1999). However, it appears that
different DA receptors play different roles in the insula in different pain conditions: the
activation of D2 and the blockade of D1 elicit antinociception in a neuropathic rat model as
measured by a decrease in the autotomy behavior, but the opposite pattern is without effects
(Coffeen et al., 2008). These data suggest that the activation of D1 receptor is pronociceptive in
a chronic pain condition (Coffeen et al., 2008), but antinociceptive in acute pain (Burkey et al.,
1999), whereas D2 activation is antinociceptive in the chronic neuropathic pain condition. As
opposed to the subcortical D1 and D2 receptors (Uchimura, Higashi, & Nishi, 1986, but see Greif,
Lin, Liu, & Freedman, 1995), the cortical D1 and D2 receptors usually result in an opposite
pattern of postsynaptic membrane polarization (i.e., depolarization vs. hyperpolarization;
Godbout, Mantz, Pirot, Glowinski, & Thierry, 1991; Parfitt, Gratton, & Bickford-Wimer, 1990);
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therefore, it is conceivable that inhibition of insula neurons by DA D2 is conducive to analgesia,
whereas activation by DA D1 is pronociceptive.
Whereas it is evident that intra-insular DA is required both for reward processing and
analgesia, more research is necessary to disentangle the roles of different DA receptors in the
insula, the downstream synaptic events, and the extent of the involvement of insular DA in all
these processes.
4.2.4. Amygdala
The amygdala is an almond-shaped structure in the medial temporal lobe containing at
least twelve subdivisions (LeDoux, 2000) and has bidirectional connections with the VTA (for
amygdalar efferents, see Fudge & Haber, 2000; for VTA efferents, see Swanson, 1982).
DAergic afferents to the amygdala arise from the substantia nigra and VTA and project via the
medial forebrain bundle (de la Mora, Gallegos-Cari, Arizmendi-Garcia, Marcellino, & Fuxe,
2009).

Since the 1950s, a considerable amount of research has been published on the

involvement of the amygdaloid complex in negative affect, particularly fear and aggression (e.g.
Fernandez De Molina & Hunsperger, 1959; LeDoux, 2000).
Exposure to a painful stimulus is obviously a threatening event, and therefore it is not
surprising that the amygdala is involved in the processing and modulation of pain 7 . Bilateral
lesions of the rat amygdala reduce emotional pain reactions such as ultrasonic vocalizations to an

7

It is important to stress that the amygdalar involvement in aversive and noxious processing is complex and not
uniformly distributed across all the amygdalar nuclei (for a review of each amygdalar nucleus involvement in pain,
see Neugebauer, Li, Bird, & Han, 2004). Moreover, even within a particular amygdalar nucleus there are regional
differences with respect to aversive processing. For example, microinjecting DA or the DA agonist bromocriptine
into the posterior, but not anterior, BLA “dose-dependently attenuated cold restraint stress (3 h at 4°C)-induced
gastric ulcer formation in rats” (Ray & Henke, 1991, p.786). There are also sex and lateralization differences in the
amygdalar involvement in aversive and noxious processing, with females, but not males, showing increased DA
release in BLA in a restraint stress paradigm (Mitsushima, Yamada, Takase, Funabashi, & Kimura, 2006), and with
right amygdala being more involved in an chronic arthritic pain paradigm in rats that the left amygdala (Ji &
Neugebauer, 2009).
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electric shock (Goldstein, Rasmusson, Bunney, & Roth, 1996) or shock-induced hyperalgesia
(Crown, King, Meagher, & Grau, 2000). Furthermore, bilateral lesions of the amygdala reduce
the antinociceptive action of morphine in the rat and cannabinoids in rhesus monkeys in a warmwater tail-withdrawal assay (Manning, Merin, Meng, & Amaral, 2001) and dramatically increase
the vocalization thresholds in the rat tail-flick test, but leave the tail withdrawal latencies
unaltered (Calvino, Levesque, & Besson, 1982). In agreement with this, Borszcz & Leaton
(2003) found that electrolytic lesions of the central amygdala (CeA) of rats preferentially
increased the tailshock threshold to elicit VADs, leaving VDS and SMR thresholds intact. These
investigators also reported the CeA lesions blocked the capacity of tailshock to support
Pavlovian fear conditioning. To the extent that the VAD threshold elevation reflects suppression
of the affective dimension of pain, microinjections of morphine into the basolateral amygdala
(BLA) result in a dose-dependent preferential increase in VAD threshold and this effect is
reversed by the administration of the opiate receptor antagonist methylnaloxonium into the BLA
(Nandigama & Borszcz, 2003).
The involvement of amygdala in pain affect is further confirmed by imaging studies in
humans, where it has been found that the amygdala activation corresponds with the subjective
perception of thermal painful stimuli, but not with intensity of non-painful thermal stimuli
(Bornhovd et al., 2002). In line with this, several imaging experiments with humans involving
placebo analgesia paradigms have shown that amygdalar activation is correlated with placebo
responses (Bingel, Lorenz, Schoell, Weiller, & Büchel, 2006; Craggs, Price, Perlstein, Verne, &
Robinson, 2008; Wager, Scott, & Zubieta, 2007). To the extent that the placebo effect engages
the neural circuitry that subserves the affective-motivational dimension of pain (for a review, see
Zubieta & Stohler, 2009), amygdalar activation in placebo conditions is preferentially correlated
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with suppression of the affective–motivational and not the sensory-discriminative dimensions of
pain.
Painful stimuli result in DAergic activation of the amygdala as microdialysis studies
showed that electric footshock or stimuli paired with electrical shocks increases DA release in
the rat amygdala (Herman et al., 1982; Young & Rees, 1998). Also, chronic inflammatory pain
in rodents induces increase in DA in the amygdala, as detected with high-performance liquid
chromatography (HPLC) (Neugebauer, Galhardo, Maione, & Mackey, 2009). Additionally,
aversive electrical stimulation of the inferior colliculus increases the DA and serotonin release in
BLA, but not CeA (Macedo, Martinez, de Souza Silva, & Brandao, 2005). These findings
suggest that aversive stimulation, whether painful or not, conditioned or unconditioned, results in
DA release in amygdala.
Unfortunately, the role of amygdalar DA with respect to pain affect and analgesia is
somewhat unclear, given the paucity of studies that conducted direct DAergic manipulations
within the amygdala coupled with pain paradigms. More research into DA involvement in pain
affect in amygdala is clearly warranted.
Nevertheless, there is indirect evidence that might shed a little light on the role of DA in
amygdala.

From a physiological point of view, opioid administration results in decreased

amygdalar excitation (for a review of opioid receptor function, see Simonds, 1988). As opposed
to morphine, DA has mainly excitatory effects in the amygdala 8 . Thus, if inactivation of the
amygdala by lesions or opioids results in affective analgesia, as suggested by the findings
8

Similar to the cingulate and insular cortices, DA in amygdala can have complex actions: the total output of
amygdala can be decreased on increased by DA, depending whether it excites directly the projection neurons, or it
inhibits them indirectly via GABAergic interneuron activation, as revealed by in vitro patch-clamp recordings in
rodents (Bissiere, Humeau, & Luthi, 2003; Kroner, Rosenkranz, Grace, & Barrionuevo, 2005). Moreover, the DA
local action in amygdala can be excitatory or inhibitory, depending whether it binds to the D1 receptors or D2
autoreceptors, respectively. Furthermore, DA can excite or inhibit local GABA interneurons in BLA (Marowsky,
Yanagawa, Obata, & Vogt, 2005).
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presented above, it would be plausible to assume that amygdalar excitation by DA will augment
pain behaviors, or, at least, would not result in analgesia. If this were the case, then less DA into
the amygdala would correlate with higher pain thresholds. But, some evidence suggests that
rodents with amygdalar DA depletion produced either by intra-amygdala 6-OHDA injections
(which results in selective catecholamine depletion, Ashford & Jones, 1976) or by a COMT
knockout (Kambur et al., 2008) have the same baseline nociceptive thresholds as controls, as
measured by response latencies in pain tests such as tail-flick, hot-plate or foot-shock. These
inconsistencies might be reconciled if the role of amygdala in processing pain in general is
considered.
With the caveat that there are differences in pain paradigms, experimental conditions and
behavioral variables which still need to be addressed, it is generally believed that the lateral and
basolateral nuclei attach emotional significance to noxious sensory information (i.e. pain affect),
which is then transmitted to the CeA, which, in turn, can send projections to the descending pain
control structures in the brainstem (e.g. PAG, rostroventral medulla - RVM) and thus modulates
pain behavior (Neugebauer, et al., 2009) 9 . The BLA is under tight regulatory control from mPFC
and DA in BLA has dual action: lifts the inhibition from the amygdalar projecting neurons that
are under tight mPFC inhibition and augments the sensory signal from cortical areas (Grace &
Rosenkranz, 2002; Rosenkranz & Grace, 1999, 2001, 2002a, b). Since DA enhances the sensory
inputs to BLA, it is proposed here that DA in the BLA also augments the processing of a noxious
stimulus by increasing the firing rate of the BLA neurons that project to CeA.

9

This view is consistent with the fear and anxiety research that suggests that the lateral and basolateral nuclei
together are a sensory interface where CS-US associations are made during aversive conditioning, whereas CeA is
the effector system that initiates the autonomic, endocrine and behavioral reactions to the aversive stimulus
(LeDoux, 2000)
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The CeA, which also receives DAergic projections that acts as modulator of the local
synapses (de la Mora et al., 2009), has dual action with respect to pain; it has been shown that
CeA manipulations (lesions or electrical stimulations) can enhance pain and can inhibit pain, by
activating or inhibiting, respectively, the neurons from the PAG that are part of the endogenous
descending pain modulatory system, depending on the negative affective state of the organism
(Neugebauer, et al., 2004). In other words, affective states like anxiety (that can be elicited by
the threat of an electric shock) do not engage the endogenous descending pain modulatory
system, but fear (elicited by exposure to three brief shocks) does so (Rhudy & Meagher, 2000),
presumably via differential CeA regulation of the PAG neurons. Also, stress induced analgesia
or hyperalgesia are well documented phenomena (for reviews of stress-induced analgesia, see
Butler & Finn, 2009, of stress-induced hyperalgesia, see Imbe, Iwai-Liao, & Senba, 2006).
Without going into detail of how fear and anxiety are produced, the main difference between
these states is the subjective emotional intensity. Therefore, it is conceivable that there is a
threshold after which the CeA initiates the endogenous pain suppression and DA is modulating
this threshold. By increasing firing rate in the BLA and potentiating the noxious sensory signals,
DA “forces” the CeA to initiate or not the endogenous opioid system, depending on the affective
encoding done in the BLA. Whether or not the CeA would initiate the opioid system depends on
the affective coloration assigned by the BLA to the noxious stimulus, on the affective state of the
organism prior to the noxious stimulation, and on the type of pain. Indeed, not all types of pain
trigger the endogenous opioid system; endogenous opioid system comes into play with prolong,
but not acute stimuli (Watkins & Mayer, 1986).
In terms of pain affect, if DA increase in the BLA results in amygdalar disinhibition, then
this would facilitate affective behaviors. The finding that intra-amygdalar DA microinjections
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attenuates morphine analgesia in a foot-shock test (Rodgers, 1977) appears contradictory with
the DAergic role proposed here, but it is not, as this test measured pain behaviors that are
organized at the spinal level. Also, this author injected DA into the cortico-medial amygdala,
and therefore there are regional differences between amygdalar nuclei to be considered. To the
extent that BLA attaches emotional significance to the painful stimulus, then it is conceivable
that DA manipulations in this region would not change the reflex latencies, but it would change
the emotional coloration of the stimulus. In other words, intra-amygdalar DA would not affect
the sensory dimension of pain, but the affective aspect, the latter of which is not being captured
by measures like reflex latencies. The same rationale would apply to the lack of changes in
nociceptive threshold found with intra-amygdalar DA depletion described above. In summary,
the evidence reviewed above suggests that DA in the amygdala serves a modulatory role,
facilitating adaptive behavioral responses to painful stimuli.

Thus, the carbachol-induced

affective analgesia obtained in the Schifirneţ & Borszcz (2007) study in the aVTA could be
partially mediated by DA release in the BLA or CeA. To test this hypothesis, further studies
should challenge directly the intra-VTA carbachol induced affective analgesia by microinjecting
DA antagonists in BLA and CeA, respectively.
Amygdalar nuclei are also involved in reward processing, as electrophysiological
recordings from monkey amygdala revealed that at least 35% of amygdalar neurons respond to
food reward consumption exclusively, with the other neurons responding to either bar pressing
for food or to the tone or light that had been associated with the reward (Nakano et al., 1987). It
appears that the involvement of the amygdala in reward processing relates to reward-related
learning, as lesions of the rat the BLA block the ability of cocaine-associated cues to lower the
threshold for ICSS (Hayes & Gardner, 2004) and impair different aspects of instrumental
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(Balleine, Killcross, & Dickinson, 2003) and Pavlovian (Hatfield, Han, Conley, Gallagher, &
Holland, 1996) conditioning.
In agreement with this, DA release in the amygdala is required for the formation of
different types of reward-related learning, as rats who received DA receptor antagonists into the
BLA fail to engage in cocaine seeking behavior under a second-order schedule of reinforcement
(Di Ciano & Everitt, 2004). Of note, DA D1 receptor blockade in the BLA significantly disrupts
the conditioned reinstatement of cocaine self-administration (Alleweireldt, Hobbs, Taylor, &
Neisewander, 2006), but it does not affect cocaine self-administration itself (See, Kruzich, &
Grimm, 2001), suggesting that the role of DA in the BLA is to regulate reward-related
associative learning, and not the basic incentive value of the reward (for an alternative view, see
Hitchcott & Phillips, 1998a, 1998c). In addition, blockade of D3 receptors in the amygdala
results in impaired Pavlovian conditioning to both natural (sucrose) and drug rewards
(amphetamine) (Hitchcott & Phillips, 1998b). Therefore, it is apparent that DA in the amygdala,
at least in the BLA, is required for reward-related learning, whether Pavlovian or operant, and
the ability of carbachol to support development of CPP in the present study when delivered into
the aVTA might be mediated also by DA release in amygdalar nuclei.
4.2.5. Other Terminal Sites
The involvement of VTA DA release in analgesia and reward processing within in NAc,
aCC, insula, and amygdala might explain the carbachol-induced affective analgesia and reward
in aVTA and pVTA, but does not fully account for the fact that there is a subpopulation of
muscarinically activated AND nicotinically inhibited neurons within the pVTA that is involved
in affective analgesia, but not in reward. One possible explanation is that these neurons project
to terminal sites that process analgesic, but not reward-related information.
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One of these putative sites is the PAG, to which the VTA sends both DAergic and
GABAergic projections (Kirouac et al., 2004). Whereas there are no reports that the PAG plays
a significant role in reward processing, there is ample evidence for the involvement of the PAG
in pain modulation and pain affect (Dostrovsky & Deakin, 1977; Guimarães, Guimarães, &
Prado, 2000; Heinricher, Cheng, & Fields, 1987; Vaccarino, Clemmons, Mader, & Magnusson,
1997).

The PAG contributes to analgesia by activating both ascending projections to the

forebrain and thalamic sites essential for the production of the affective dimension of pain and
descending projections to the rostral ventromedial medulla that result in the suppression of pain
transmission at the level of spinal cord (Behbehani, 1995; Borszcz, 1995, 1999). For example,
the affective analgesia obtained after morphine microinjections into the nucleus parafascicularis
thalami (nPf) is blocked by muscimol (GABAA agonist) injections in the ventrolateral PAG
(Munn et al., 2009). Alternately, the analgesia induced by morphine injections in the ventral
PAG is dose-dependently reduced by administration of methysergide (5-HT antagonist) in the
CeA or nPf (Borszcz & Streltsov, 2000).
These results suggest that there is a functional interaction between PAG, CeA and nPf in
modulating the affective dimension of pain. Thus, it is conceivable that the analgesic, but notrewarding effect of muscarinically activated and nicotinically inhibited neurons within the pVTA
is possibly mediated by their projections to PAG, a site paramount for antinociception, but not
for reward-related processing.
4.3. The Role of the VTA DA in Analgesia and Reward
4.3.1. Reinforcement and Reward: The Masking Hypothesis
The data presented above emphasizes the role of cholinergically-induced DA release
from the VTA in affective analgesia and reward. But the question of how is DA exactly
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producing analgesia and reward in each of the structures discussed above is still unanswered.
Namely, is DA producing analgesia by suppressing the pain transduction and thus disrupting the
pain circuitry? Or is the activation of the VTA DA inducing a positive affective state that is
superimposed on the negative affective state produced by pain and thus attenuating the pain
experience? In an attempt to answer these questions, in the following section I will discuss some
of the most prominent hypotheses regarding the role of DA in general and then, based on the
available evidence, provide a framework for understanding the role of DA in pain, analgesia, and
reward in the context of DA function.
4.3.1.1. Nucleus Accumbens Evidence
Since its discovery as a neurotransmitter and not just a precursor of norepinephrine and
epinephrine in 1957 (Carlsson, Lindqvist, & Magnusson, 1957) for which Carlsson received the
Nobel prize, DA is incontestably the molecule for which more hypotheses have beet put forward
than for any other neurotransmitter. There has been so much research of DA and DA function(s)
in addiction, for example, that this neurotransmitter achieved the status of celebrity both in the
scientific world and in the popular media as the ‘pleasure molecule’ (Marsden, 2006). As DA
has definite roles in Parkinson disease, schizophrenia, pair-bonding, cardiovascular regulation,
kidney function and others, only a few of the hypotheses - regarding reward and reinforcement are briefly discussed in the following pages, as they are the most relevant to pain and analgesia.
Out of these, the most known hypothesis (and oldest) is usually referred to as the hedonic
hypothesis of DA or simply the reward hypothesis 10 .

10

Proposed initially by Wise (Wise, 1982; Wise, Spindler, deWit, & Gerberg, 1978), the anhedonia hypothesis has
been refined and enlarged to include as separate subdivisions the DA involvement in reinforcement, reward,
incentive motivation, and hedonia (see Wise, 2004, 2008). Here are highlighted only the major concepts that
received the most empirical support.
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According to the reward hypothesis, the role of DA in appetitive reinforcement is thought
to convey the reward signal itself (Wise, 1996) and when this signal is blocked (e.g. by DA
antagonists), the “goodness” of the stimuli is blunted:
In introspective language we would say that neuroleptics [that disrupt the midbrain
dopamine system] appear to take the pleasure out of normally rewarding brain
stimulation, take the euphoria out of normally rewarding amphetamine, and take the
“goodness” out of normally rewarding food (Wise, Spindler, deWit, & Gerberg, 1978, p.
263).
As seen in Chapter 1.2., this hypothesis received substantial support from studies that
assessed both the reinforcing and the rewarding effects of DA agonists. Drugs of abuse like
opioids and psychostimulants act as DA agonists as they increase the DA availability in the
brain. Such drugs have high abuse potential, are self-administered in both animals and humans,
and as outlined in Chapter 1.2., they are also potent analgesics. Based on this observation, as
described in Chapter 1.3., Altier and Stewart (1999a) proposed that these drugs act as analgesics
because they shift the motivational state from a negative affective state, such as that produced by
a painful stimulus, to a normal affective state by promoting the DA availability into the NAc.
On the other hand, these drugs achieve addictive liability when administered in a normal
affective state, because they shift the motivational continuum from a neutral affective state
towards a positive affective state, by promoting DA availability into the same site, i.e. NAc (Fig.
1).
Of course, one can find many caveats with the accumbal DA hypothesis of reward. For
instance, Ikemoto (2007) pointed out that the pleasure felt during anticipation of reward is
different (and thus probably subserved by different neural mechanisms) from the sensory
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pleasure of the consumption of reward. Whether DA is necessary or is merely modulating these
two types of pleasure it is still unclear. Another problem stems from the techniques employed to
asses the role of DA. To mention only one example, the CPP paradigm is often used for
measuring reinforcement of a particular drug, even though CPP is a form of Pavlovian learning,
and not operant, thus being more suitable for reward measurement (Wise, 1996; Wise &
Rompre, 1989).
Nonetheless, the reward hypothesis has dominated DA research for the past 25 years and
the fact the DA release in NAc is associated with at least some form of a positive state is a welldocumented phenomenon. Corroborating this with the finding that DA release/availability in
NAc is also associated with analgesia, it seems plausible that the way in which mesoaccumbal
DA mediates affective analgesia in the present study is by producing a positive affective state
that shifts the motivational continuum towards the middle, as Altier & Stewart (1999a)
suggested. In doing so, accumbal DA effectively masks the negative affect produced by pain and
shifts the motivational continuum to a more positive affective state that would allow the
organism to more effectively ignore the pain and engage in adaptive behaviors destined to escape
the noxious stimulus and/or to avoid further injury.
4.3.2. Salience: The Pain Transmission Suppression/Facilitation Hypothesis
However, the DA theory of reward is incomplete, as it cannot account for the fact that
reward without DA is possible. In a series of experiments with DA-deficient mice created by
inactivating the tyrosine hydroxylase gene, the Palmiter group (Zhou & Palmiter, 1995) found
that these mice will die of starvation if DA is not restored to the striatum because they do not
approach food placed literally in front of their noses (Hnasko, Szczypka, Alaynick, During, &
Palmiter, 2004) or they eat such insignificant amounts of food that are not enough to keep them
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alive (Szczypka et al., 1999), but they still prefer sucrose over water (Cannon & Palmiter, 2003).
Additionally, neurochemical 6-OHDA lesions of the NAc do not disrupt the ‘liking’ of sweet
solutions, as assessed by the taste reactivity test (i.e., observing the evolutionarily conserved
affective reactions of rats to sucrose, Berridge & Robinson, 1998). With respect to drugs of
abuse, the DA-depleted mice display robust CPP with morphine (Hnasko, Sotak, & Palmiter,
2005) and cocaine (Hnasko, Sotak, & Palmiter, 2007), suggesting that the ability of these drugs
to induce a positive affect must either 1) not rely on DA or 2) relies on DA, but in the absence of
it, a compensatory mechanism mimics the DA action.

Because fluoxetine, a serotonin

transporter blocker, induces CPP in the DA-depleted animals, but not in the control animals
(Hnasko et al. 2007), it seems that the second explanation is more plausible.
Moreover, the reward hypothesis of DA function predicts that the A10 neurons should be
inhibited, or, at least, should not fire in the presence of an aversive stimulus. If DA signals to the
NAc carry a positive affect and fire only during presentation or expectation of rewards, then one
would expect the DA neurons to be silent during aversive stimulation. Indeed, an experiment
employing in vivo electrophysiological recordings has shown that DA neurons within VTA are
uniformly inhibited during foot pinch of anaesthetized rats whereas the non-DAergic neurons are
activated (Ungless et al., 2004). However, as shown in Table 1, there is considerable evidence
that VTA DA neurons are active during aversive stimulation like tail pinch (Smith et al., 1997)
and this activation is associated with increased accumbal DA (Young, 2004). In light of this
evidence, the same group that found that DA neurons are uniformly inhibitive during noxious
stimulation, repeated their previous experiments and found that dorsal VTA (PBN) does not
respond to noxious stimulation (consistent with the reward hypothesis), but ventral VTA (PN)
shows phasic activation by electric footshocks (Brischoux, Chakraborty, Brierley, & Ungless,
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2009). Thus, there are at least two different populations of neurons within the VTA that have
different firing patterns to negatively or positively valenced stimuli.
As a consequence of these and similar findings, the incentive salience hypothesis of DA
has been put forward, initially by Berridge and Robinson (Berridge & Robinson, 1998; Robinson
& Berridge, 1993, 2003), and then refined and expanded by others.

According to this

hypothesis, the DA signal does not carry the hedonic value of a stimulus (the ‘liking’), rather it
carries a different component of reward, the ’wanting’. In other words, during the process of
Pavlovian learning, DA mediates the transformation of the neutral representation of the
conditioned stimulus into an attractive and ‘wanted’ incentive that ‘grabs attention’, thus the
reinforcing stimuli acquire incentive motivational properties. For example, both a light that will
predict an electric shock and the sight of palatable food will increase DA release, because both
stimuli need to ‘grab the attention’ of the animal as they are salient events for the organism.
However, additional data suggest that the incentive motivational role of DA extends beyond
conditioned stimuli. Supporting this idea, data from electrophysiology and microdialysis studies
have shown that a wide range of salient unconditioned stimuli like pain, loud tones, bright lights,
and novel environments increase the firing of DA neurons (for a review of these studies, see
Horvitz, 2000).
The incentive-salience theory and its derivatives shift the focus of DA neurons as reward
detectors to a broader role as high relevance for behavior or salient stimuli detectors (Salamone,
Correa, Mingote, & Weber, 2005). With respect to aversive stimulation, this theory implies that
VTA neurons are involved in processing both aversive and appetitive stimuli, as long as they
display incentive salience properties.
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Thus, the VTA DA signals a change in the environment that is of importance for the
animal. This signal is not devoid of meaning (of which the animal might be aware of or not)
because a salient stimulus or event has motivational properties; it requires the organism to be
ready for a potential change in the environment and therefore be able to engage in a goaldirected behavior that is responsive to that environmental change. Therefore is not surprising
that a painful stimulus, which is a change in the environment that has incentive-motivational
properties, results in massive DA release in various brain structures.
4.3.2.1. Anterior Cingulate Cortex Evidence.
Pain is a complex experience that captures attention, it is a salient event, and requires
“alerting and orienting to the potentially threatening stimulus, evaluating and anticipating the
threat and executing an appropriate escape response, as well as learning and memory to avoid
future encounters” (Hutchison, Davis, Lozano, Tasker, & Dostrovsky, 1999, p. 404).
The aCC is a structure implicated in performance monitoring and error detection
(Bechtereva, Shemyakina, Starchenko, Danko, & Medvedev, 2005) and attentional processes
(for a review, see Raz & Buhle, 2006), and its role in attention is to “focus greater attention on
behaviorally relevant stimuli to limit the processing of distracting events” (Weissman,
Gopalakrishnan, Hazlett, & Woldorff, 2005, p. 229). In addition, the evidence presented in
Chapter 4.2.2. outlines 1) the role of aCC in generating the affective dimension of pain, 2) the
role of DA release in aCC in producing affective analgesia, and 3) the role of DA release in aCC
in reward and drug self-administration.
Therefore, it is proposed here, and in concordance with the motivational-incentive
hypothesis of DA function, that the role of DA in aCC is to prevent the generation of the
affective dimension of pain in order to shift attention to goal-directed behaviors that would result
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in an escape from the painful stimulus. Thus, the saliency signal is effectively transformed into a
pain suppression signal in the aCC enabling generation of behaviors more important for the
organism, like escaping, attending to the injury, or preventing further injury.

Pain is

unquestionably a salient event, but perhaps the need, the ‘want’ to escape pain and its causes is
more salient and it is possible that this information is what VTA conveys to the aCC.
Likewise, during drug-self administration, the DA signal of the aCC could carry
incentive-motivational information relevant for orienting/shifting attention, error detection,
and/or performance monitoring destined to prepare the organism for goal-directed behavior.
Indeed, one line of evidence links the VTA DA neuronal firing more to the expectation of
rewards rather than the hedonic value of the stimulus, particularly in the neocortical regions
(Schultz, 2002). Therefore, the fact that intra-aCC DA antagonists block diverse aspects of selfadministration and reinforcing properties of drugs of abuse might not necessarily reflect a
reduction of the hedonic value of the stimulus carried by the DA release in the aCC, but rather a
reward expectation signal that is disrupted (i.e. a salient event is about to happen).
4.3.2.2. Insula Evidence.
It is plausible that a saliency signal is generated not only in response to relevant external
events, but also to the events that change the internal equilibrium of the organism. As both
external events like a painful stimulus and drugs of abuse result in interoceptive changes, the
insular cortex plays a central role in creating and updating a neural map of these bodily changes
that serve the purpose of maintaining homeostasis. It is believed that the insular cortex, along
with other structures, is a part of a circuit that attaches emotional valence to these interoceptive
changes. Indeed, there is evidence that the activity of the insula is strongly associated with some
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of the feelings associated with interoceptive changes like disgust (Wicker et al., 2003), craving
(Contreras et al., 2007), and the unpleasantness of pain (Greenspan et al., 1999).
As outlined in Chapter 4.2.3, the DA input to the insular cortex is essential for both
analgesia and reward processing. Integrating the data presented above and taking into account
the general homeostatic role of insula in reward and analgesia, it is hypothesized here that the
DA signal to the insular cortex brings information vital to the updating the neural map of the
current state of the organism with the purpose of restoring homeostasis. This hypothesis is
consistent with the incentive-motivational role of DA.
Correspondingly, the analgesia that follows DAergic activation of the insula might be the
result of a process of pain transmission suppression, a process similar to the prevention of the
generation of the affective dimension of pain in the aCC. Indeed, both insula and aCC are
involved in the generation of the affective dimension of pain, although the unpleasantness of
pain serves different purposes in these two areas: whereas insula integrates different signals from
the body, attaches emotional valence to them and makes these feeling available to consciousness,
the aCC supplements the motor aspect of motivations to emotional stimuli (volition, agency)
(Craig, 2009a, 2009b). Therefore, DA in insula IF it binds to D2 receptors (see Chapter 4.1.2.)
might prevent the pain unpleasantness from either being generated or from being made available
to awareness. In either case, the behavioral result is affective analgesia. On the other hand, IF
DA binds to the D1 receptors, then the result could be a heightened signal regarding the saliency
of the pain stimulus, thus facilitating the insular cortex in the generation of the conscious feeling
of unpleasantness. It would be interesting to investigate the circumstances under which D1 or D2
receptors are activated.
4.3.2.3. Amygdala Evidence
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The modulatory role of the DA saliency signal is even more apparent in the amygdala.
As mentioned above, the BLA and the CeA nuclei have distinct roles in pain processing: the
BLA attaches negative emotional valence to stimuli, whereas the CeA is the effector, it “acts” on
the input provided by BLA. This type of connection parallels the relationship between insular
and cingulate cortices. However, the DA input to amygdala, whereas it still brings a saliency
signal, has a different role than the input to the two cortical areas. Namely, the DA release into
the BLA augments the pain signal, consistent with the salience-motivational hypothesis of DA
function. It is proposed that this augmentation facilitates adaptive responses to the painful
stimuli.
Electrophysiological recordings from CeA during application of DA in a painful setting
have not yet been conducted, but the available evidence summarized in Chapter 4.2.4. suggests
that DA is capable to modulate the CeA output during pain. As a consequence, the CeA can
either activate or inhibit the endogenous opioids release, as CeA projects to and modulates the
descending pain modulatory system subserved by PAG and RVM (Neugebauer et al., 2009). At
prima facie, it would seem paradoxical that organisms do not make use of the endogenous opioid
system every time a painful stimulus occurs, regardless of type or situation. And yet, one can
think of a situation when an augmentation of the painful stimulus (like chronic pain,
inflammation) (read amygdalar activation and inhibition of the endogenous opioids) would be
adaptive, because it forces the organism to pay attention and take action, thus avoiding further
injury. On the other hand, “in life-threatening situations (actual or perceived), when survival
demands ‘fight or flight’-like decisions, the amygdala acts to suppress attention to pain as a less
important but possibly distracting factor to guarantee survival” (Neugebauer, 2007, p. 2).
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Perhaps DA in amygdala provides a gate for aversive stimuli enabling a switch between starting
on and shutting off the endogenous opioid system.
With respect to reward processing within amygdala, it is possible that the disruption of
different reward-related learning tasks by DA antagonists reflects the absence of a signal that
conveys the incentive-motivational value of a rewarding stimulus. Amygdala would require
such a signal to perform adequate reward-related learning with the purpose of adaptive goaldirected behavior. Indeed, the impairments seen in cocaine seeking behavior (Di Ciano &
Everitt, 2004) or conditioned reinstatement of cocaine self-administration behavior (Alleweireldt
et al., 2006) after intra-BLA microinjections of DA antagonists might reflect the disruption of a
motivational signal destined to facilitate reward-related learning phenomena.
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CHAPTER 5. CONCLUDING REMARKS
In summary, the present study is the first to systematically evaluate and compare the
extent of the overlap between the neuronal circuits underlying reward and affective analgesia by
investigating the participation of the cholinergically activated DA release from three VTA
subregions in reward and affective analgesia. Additionally, by analyzing the two major theories
of DA function – the reward theory and the salience theory -, it is hypothesized here that VTA
DA plays different roles in reward and analgesia, depending on the terminal region.
In the NAc, VTA DA is not interfering directly with the pain processing system, but it
induces affective analgesia by producing a positive affective state that is superimposed on the
negative affective state produced by pain and thus masking pain affect. In other words, both the
unpleasantness of pain and the pleasant feeling generated by the DA release in NAc are
simultaneously processed in the brain, but they compete for what economists and computational
theorists termed resource allocation. Competition between opposing motivational system has
long been hypothesized by psychological theories such as the Opponent Process Theory
proposed by Solomon & Corbit (1974) and supported by Koob & Le Moal (2008) or the
Motivation-Decision Model proposed initially by Fields (2007) and refined later by Leknes &
Tracey (2008). By themselves, both pain and reward are powerful motivational states that result
in a learning signal to either avoid or approach, respectively, the environmental stimulus or
situation that caused them. This “teaching signal” (Fields, 2004, p. 571) is used by other brain
regions (presumably cortical) for decision-making processes and goal-directed behaviors
destined to keep the actions of the organism adaptable and coherent. When both these powerful
teaching signals occur together, pleasure and unpleasantness compete for processing resources,
because cortical areas like the aCC and PFC must act based on one signal, but not the other,
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since approach and avoidance are behavioral actions that cannot be performed simultaneously.
The positive affect generated by DA release in NAc during a painful state competes with the
negative affect generated by the noxious stimulus, thus masking the pain signal and shifting the
motivational balance toward a more positive affective state. This idea is concordant both with
the motivational continuum theory proposed by Altier & Stewart (1999a) and with the reward
hypothesis of DA function.
On the other hand, DA release in other brain regions effectively suppresses or facilitates
the pain signal, concordant with the incentive-motivational theory of DA function. Specifically,
DA release in the aCC and in the insula (when binding to D2 receptors) suppresses the pain
transmission circuitry, but DA release in the amygdala (particularly the BLA) and in the insula
(when binding to D1 receptors) facilitates the pain signal. Presumably, DA release in these
regions increases the saliency of either the pain signal or the need to escape pain, depending on
which is more adaptive for the organism at a given time. Thus, the salient signal carried by DA
can serve as 1) a suppressor of the generation of the affective dimension of pain in the aCC in
order to shift attention to goal-directed behaviors designed to escape injury, 2) a suppressor or
facilitator of the pain signal in insula in order to enable behaviors designed to achieve
homeostasis, and 3) a modulator of the endogenous descending pain modulatory system in
amygdala in order to enable adaptive responses to pain.
In summary, when DA reaches its terminal regions, it seems that it is differently utilized
by these structures. Thus, the reward and salience hypotheses are not incongruent with each
other; rather they are complementary theories.
In conclusion, major challenges remain, not the least of which is the understanding of the
production and suppression of the affective dimension of pain. However, it is apparent that the
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brain’s ‘pleasure molecule’ plays a significant role in the modulation of the affective reaction to
pain. The obvious importance of the pain affect to the pain experience and the necessity of
finding a potent analgesic that lacks abuse potential clearly warrant further studies.
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APPENDIX A. TABLES
Table 1
VTA-NAc pathway involvement in reward and reinforcement
Species

Behavioral
paradigm

Method

Main Results

Reference

Humans

Oral intake of
alcohol or
orange juice
30 min prior
to tracer
injection

PET with
[11C]
raclopride
(D2
radioligand),
MRI

Radiotracer binding potential was reduced bilaterally
in the NAc in the alcohol condition compared to the
orange juice condition, indicative of increased
extracellular DA. The magnitude of the change in
radiotracer binding correlated with the alcoholinduced increase in heart rate, which is thought to be a
marker of the psychostimulant effects of the drug.

Boileau et al.,
2003

Rats

CPP

Intra-VTA
morphine

Morphine supports CPP learning in the VTA, but not
in the adjacent areas.

Bozarth, 1987

Humans

Smoking
inside the
scanner

PET with D2
radiotracer,
genotyping

Smokers with genes associated with low resting DA
tone have greater smoking-induced (phasic) DA
release into ventral caudate/NAc during smoking than
those with alternate genotypes.

Brody et al.,
2006

Rats

ICSS of MFB

E-PHYS,
FSCV

ICSS elicited DA release in the NAc and produced
coincident time-locked changes (predominantly
inhibitions) in the activity of a subset of NAc neurons.
Similar responses were elicited with noncontingent
stimulations. The changes in firing rate induced by
noncontingent stimulations were reversed by the
GABAA receptor antagonist bicuculline.

Cheer, Heien,
Garris,
Carelli, &
Wightman,
2005

Rats

i.v. CB
agonists and
antagonists

FSCV

The CB agonist produced dose-dependently increases
extracellular NAC DA and this is manifested as an
increase in the frequency and amplitude of rapid DA
transients in the NAc. These effects are reversed by a
CB1 antagonist.

Starved
rats

Instrumental
learning for
food pellets

microdialysis

The rats that learned the task showed significantly
higher increases in NAc DA than rats that did not
learn the task in the first session. The NAc DA
increase was similar in both learning groups in the
second session.

Cheer,
Wassum,
Heien,
Phillips,
Wightman,
2004
Cheng &
Feenstra,
2006

Rats

i.p. or s.c.
drug
administration

microdialysis

Drugs abused by humans (e.g., opiates, ethanol,
nicotine, amphetamine, and cocaine) increased
extracellular DA in NAc. Drugs with aversive
properties (e.g., agonists of K opioid receptors, U50,488, tifluadom, and bremazocine) reduced NAc
DA. Drugs not abused by humans [e.g., imipramine
(an antidepressant), atropine (an antimuscarinic drug),
and diphenhydramine (an antihistamine)] failed to

Di Chiara &
Imperato,
1988
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modify synaptic DA concentrations.
Humans

i.v.
amphetamine

Rats

ICSS of VTA

Humans

Instrumental
tasks for
amphetamine

Rats

PET with
[11C]
raclopride
(D2
radioligand)
microdialysis,
HPLC

The magnitude of NAc DA release and binding
correlates positively with the hedonic (euphoric)
response to amphetamine.

Drevets et al.,
2001

Increases in extracellular NAc DA were positively
correlated with the rate of ICSS.

Fiorino et al.,
1993

NAc
cannulation

Rats will perform different variants of instrumental
tasks in order to receive direct intra-NAc injections of
amphetamine.

Cocaine selfadministration

FSCV

NAc DA levels increased during perception of
cocaine-associated cues, during lever-pressing for
cocaine, and during consumption of cocaine.
Remarkably, these behaviors could be elicited by
electrically evoking NAc DA release from the VTA.

Hoebel,
Monaco,
Hernandez,
Aulisi,
Stanley, et al,
1983
Phillips et al.,
2003

Humans

i.v. cocaine

PET with
[11C] cocaine
(DAT)
radioligand

Cocaine at doses commonly abused by humans
blocked between 60-77% of DAT in the dorsal
striatum (whose DAT response to cocaine is similar to
NAc). This occupancy was positively correlated with
the subjective reports of high and rush. The DAT
occupancy must be greater than 47% for cocaine users
to subjectively perceive cocaine as rewarding.

Volkow et al.,
1997

Rats

ICSS of
VTA/MFB

E-PHYS

NAc neurons exhibit vigorous activation, both
antidromically and orthodromically, in response to
self-administered trains of stimulation in VTA/MFB.

Rats

Heroin i.v.
selfadministration

FSCV

Heroin self-administration increased the extracellular
NAc DA, in a dose-dependent and naloxonereversible manner.

Wolske,
Rompre,
Wise, &
West, 1993
Xi, Fuller, &
Stein, 1998

Mutant
mice
(TH -/-)

Feeding and
locomotion
recording

i.p. injections
of L-DOPA,
quinpirole
and SKF
81297

Although the mutant mice behave and develop
normally for the first postnatal week, they display
symptoms of bradykinesia and hypophagia and they
will die of starvation by 3 to 4 weeks without
intervention. Restoration of DA function by L-DOPA
induces near normal activity, feeding, and growth
levels.

Zhou &
Palmiter,
1995

Note: A query on the search engine Stanford HighWire (that includes PubMed) to contain the
words “dopamine”, “accumbens”, and “reward”, all in the same abstract, rendered 817 results on
May 1st, 2010. Thus, only a handful of the studies that seemed most relevant to the topic
described herein were included in this table, in alphabetical order.
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Abbreviations.

CB – cannabinoid; CPP – conditioned place preference; E-PHYS –

electrophysiological recordings; FSCV – in vivo fast-scan cyclic voltammetry; ICSS – intracranial self-stimulation; HPLC – high performance liquid chromatography; fMRI – functional
magnetic resonance imaging; PET – positron emission tomography; TH – tyrosine hydroxylase.
Table 2
VTA involvement in pain
Species

Behavioral
paradigm

Metho
d

Main Results

VTA
involveme
nt

Cell
type

Reference

Human
s

Noxious
thermal
stimuli
(46°C)

fMRI

Noxious stimuli increased the signal
several brain regions implicated in
reward processing, such as the
VTA/PAG region and extended
amygdala, among other structures.

Activation

N/A

Becerra,
Breiter, Wise,
Gonzalez, &
Borsook,
2001

Anesth
etized
rats

Footshock

Dorsal VTA is inhibited by footshocks,
the ventral VTA is phasically excited
by footshock.

Excitation
and
inhibition

DA

Brischoux et
al., 2009

Human
s

Noxious
electrical
stimuli to
either the
midline
lower
abdomen or
rectum
Noxious
thermal
stimuli to
the hand
accompanie
d by visual
cues
Noxious
mechanical
stimulation
of the skin

EPHYS,
JCL,
TH
IHC
fMRI

Increases in signal were observed in the
VTA/SN, PAG, parabrachial
nuclei/nucleus coeruleus, and red
nucleus bilaterally to both stimuli.

Activation

N/A

Dunckley et
al., 2005

fMRI

Increases in signal were observed in the
VTA and other regions before and
during pain. Activation of insula
during pain was predicted by activity in
both the entorhinal cortex and VTA
during anticipation of pain.

Activation

N/A

Fairhurst,
Wiech,
Dunckley, &
Tracey, 2007

EPHYS

Following application of noxious
stimuli, 37% (n=14) of the VTA cells
were inhibited, 58% (n=22) showed no
response, and 5% (n=2) were excited.

N/A

Hentall, Kim,
& Gollapudi,
1991

c-fos
IHC

Tonic pain activates DAergic and
CCKergic neurons from the VTA.

Mostly
inhibition
or
unresponsi
ve
Activation

DA,
CCK

Ma, Zhou, &
Han, 1993

Human
s

Anesth
etized
rats
Rats

Formalin
test

82
Anesth
etized
rats

Foot pinch,
tail pinch,
stimulation
of the
vaginal
cervix

EPHYS

For foot pinch and tail pinch tests,
suppression of DA neurons occurred
more frequently than activation (68%
vs. 13%). For the same tests, the nonDA neurons half had decreased activity
(43%) and half had increased activity
(46%).

Mostly
inhibition

DA,
nonDA

Maeda &
Mogenson,
1982

Anesth
etized
rats

Noxious
tail-pinch

EPHYS

The mesocortical DA neurons
responded to tail pinch, either by an
excitation (65%), or by an inhibition
(25%). In contrast, most DA neurons
projecting either to the NAc or the
septum remained unaffected.

Mostly
inhibition

DA

Mantz,
Thierry, &
Glowinski,
1989

Rats

Tail-shock

NAc
microdi
alysis

Both tail-shock and intra-VTA
capsaicin induce DA release in NAc,
and this release is blocked by intraVTA microinjection of the TRPV1
antagonist iodoresineferatoxin.

Excitation

DA

Rats

Formalin
injections
into the
lumbar
muscles and
skin
Tail pinch

c-fos
IHC

Fos-immunoreactive neurons were
observed in the VTA, spinal cord, NAc
core, BLA, PAG and other regions

Activation

N/A

Marinelli,
Pascucci,
Bernardi,
PuglisiAllegra, &
Mercuri, 2005
Ohtori et al.,
2000

c-fos
IHC

More Fos-immunoreactive neurons
were observed in the VTA and other
regions of the young rats than the
middle-aged rats

Activation

N/A

Smith et al.,
1997

Anesth
etized
rats

Foot pinch

EPHYS

The VTA neurons that are excited by
aversive stimuli are not DAergic; the
DA neurons are uniformly inhibited.

Excitation
and
inhibition

DA,
nonDA

Ungless,
Magill, &
Bolam, 2004

Rats

Footshock

NAc
microdi
alysis

DA levels in NAc increased after each
shock.

Excitation

DA

Young, 2004

Young
and old
rats

Abbreviations. BLA – basolateral nucleus of the amygdala; IHC – immunohistochemistry; JCL juxtacellular labeling.
Table 3
VTA involvement in analgesia
Species

Behavioral
paradigm

Method

Main Results

Reference
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Rats

Formalin test

Tail flick test
Rats

Formalin test

Rats

Formalin test

Rats
Rats

Formalin
test, Tail
flick test
Formalin test

Rats

Formalin test

Rats

Aversive
electrical
stimulation
of the NRGi
Formalin test

Rats

Rats

Rats

Rhizotomy
(section of
dorsal roots
C5 to Th1
included)
The VAD
test

Rats

Tail or foot
pinch tests

Rats

Formalin test

Bilateral intra-VTA
infusions of the
Substance P analogue,
DiMe-C7
Bilateral infusions of
amphetamine into the
medial prefrontal cortex
Bilateral infusions of
amphetamine into the
NAc
Intra-VTA DiMe-C7 or
intra-NAc amphetamine
Intra-VTA infusions of
the opioid antagonist
naltrexone
intra-VTA infusions of
neuropeptide FF

DiMe-C7 induced analgesia

Altier &
Stewart, 1993

Amphetamine failed to induce analgesia
Amphetamine induced analgesia
No analgesia
Reduced stress-induced analgesia

Altier &
Stewart, 1996

Blocked analgesia induced by
intro-VTA morphine or exposure to
footshock stress

Altier &
Stewart, 1997a

Intra-VTA or intra-NAc
infusions of tachykinin
agonists
Intra-NAc infusions of
DA antagonists

All injections produced analgesia in the
formalin, but not in the tail-flick test

Altier &
Stewart, 1997b

Blocked the analgesia induced by intraVTA infusions of the substance P analog,
DiMe-C7 or morphine and intra-NAc
infusions of amphetamine

Altier &
Stewart, 1998

Intra-VTA infusions of
the tachykinin NK-l
receptor antagonist, RP67580
ICSS of VTA

Blocked footshock stress-induced
analgesia

Altier &
Stewart, 1999b

Long-lasting suppression of aversion
produced by the NRGi following VTA
brain stimulation

Anderson et
al., 1995

6-OHDA lesion of the
NAc

The lesion reduced the analgesic effect of
amphetamine, but had no effect on
morphine analgesia

Clarke &
Franklin, 1992

6-OHDA lesion of the
VTA

The lesion induced an increase in the
autotomy behavior

Gorea &
Lombard, 1984

Intra-VTA
microinjections of
carbachol and atropine

Carbachol induced affective analgesia in a
dose-dependant manner and this effect
was blocked by atropine. Carbachol had
no effect on the SMR thresholds

Kender et al.,
2008

Intra-VTA infusions of
the GABA-A agonist
muscimol
Intra-VTA
microinjections of the
opioid antagonist
naloxone, s.c. morphine

Muscimol potentiates the analgesia
induced by i.p. halothane or pentobarbital

Ma & Leung,
2006

Morphine produced almost complete
analgesia in the Phase 2 of the formalin
test that was not reversed by 3 μg
naloxone.

Manning &
Franklin, 1998
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Rats

Tail-flick
test

Electrical stimulation of
the VTA

Analgesia

Mayer, Wolfle,
Akil, Carder, &
Liebeskind,
1971
Morgan &
Franklin, 1990

Rats

Formalin
test, tail-flick
test

6-OHDA lesion of the
VTA

The lesion blocked the analgesic effect of
amphetamine and morphine in the
formalin, but not in the tail-flick test.

Rats

Hot plate test

Electrical lesion of the
VTA

No effect on the analgesia induced by
morphine or the κ-opioid agonist U50,488H.

Ohno,
Yamamoto, &
Ueki, 1987

Rats

Acute and
chronic pain
tests

Selective chemical
lesions with 6-OHDA
or/and kainic acid of the
VTA, SN and striatum

All lesions of DAergic terminals in the
striatum decreased the latencies of all
nociceptive reflexes and accelerated the
time of onset of autotomy behavior.
Kainic acid lesions of the SN-VTA did not
produce significant changes in the
latencies of nociceptive reflexes or in the
autotomy criteria.

Saade, Atweh,
Bahuth, &
Jabbur, 1997

Rats

The VAD
test

Intra-VTA
microinjections of
carbachol,
mecamylamine, and
atropine

Carbachol induced affective analgesia in a
dose-dependant manner in both anterior
and posterior VTA. This effect was
blocked by atropine and mecamylamine in
anterior VTA and by atropine in posterior
VTA. Carbachol had no effect on the
SMR thresholds.

Schifirneţ,
2009

Rats

Carrageenan
inflammation
of the paw

Radiofrequency lesions
or electrical stimulation
of the VTA

VTA lesions enhanced the occurrence of
autotomy behavior, whereas VTA
stimulation facilitates analgesia

Rats

Formalin test

Intra-NAc D1 and D2
agonists and antagonists
administration

Quinpirole dose-dependently inhibited the
Phase 2 nociception in the formalin test,
effect that was blocked by raclopride,
suggesting that the NAc D2 receptors are
involved in antinociception. The D1
agonist results were inconclusive.

Sotres-Bayon,
Torres-Lopez,
Lopez-Avila,
del Angel, &
Pellicer, 2001
Taylor et al.,
2003

Mice

Formalin test

Systemic administration
of DAergic agents

Both D1 and D2 receptors agonists and
antagonists induced antinociception in
different phases of the formalin test.

Zarrindast,
Nassiri-Rad, &
Pazouki, 1999

Abbreviations. 6-OHDA – 6-hydroxydopamine; NRGi - nucleus reticularis gigantocellularis.
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Activation of the dopaminergic mesolimbic reward circuitry that originates in the ventral
tegmental area (VTA) is postulated to preferentially suppress affective reactions to noxious
stimuli (affective analgesia, AA). VTA dopamine neurons are activated via cholinergic inputs,
and we have observed that microinjections of the acetylcholine agonist carbachol suppressed
vocalizations of rats that occur following administration of brief (1 sec) tail-shocks (vocalization
afterdischarges = VAD). VADs are a validated rodent model of pain affect. In addition, the
capacity of carbachol to support reinforcement appears to be regionally dependent within VTA.
Ikemoto & Wise (2002) reported that carbachol was self-administered in the posterior VTA
(pVTA), but not the anterior VTA (aVTA). We have previously reported that carbachol
preferentially increased the threshold current intensity for eliciting VADs in aVTA and pVTA,
but not midVTA. This carbachol-induced AA is mediated by muscarinic receptors within the
pVTA and by both muscarinic and nicotinic receptors within the aVTA. Using the conditioned
place preference paradigm (CPP), the present study evaluated the muscarinic versus nicotinic
involvement in intra-VTA carbachol-induced CPP learning by administering atropine

132
(muscarinic antagonist) and mecamylamine (nicotinic antagonist) into the VTA prior to
carbachol treatment. The present study indicates that unilateral carbachol (4 µg/0.25 µl) supports
the CPP learning in aVTA and pVTA, but not midVTA. Additionally, both atropine (60 µg/0.25
µl) and mecamylamine (45 µg/0.25 µl) reliably prevented the development of carbachol-induced
CPP in the aVTA and pVTA. Thus, this study is the first to directly compare the extent of
overlap between cholinergically mediated reward and affective analgesia within different VTA
regions. The results are discussed in terms of anatomical and physiological properties of the
VTA, with emphasis of cholinergically activated mesolimbic and mesocortical systems. Finally,
based on two of the most prominent hypotheses regarding the role of DA in general, a
framework is provided for understanding the role of DA in pain, analgesia, and reward in the
context of DA function.
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